10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-Q

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

OR

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number:  000-32179

EXACT SCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE	02-0478229
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification Number)
441 Charmany Drive, Madison WI	53719
(Address of principal executive offices)	(Zip Code)

(608) 284-5700 (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x  No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer x
Non-accelerated filer o	Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No x

As of July 31, 2013, the registrant had 70,698,697 shares of common stock outstanding.

EXACT SCIENCES CORPORATION

INDEX

		Page
		Number
Part I - Financial Information
Item 1.	Financial Statements
	Condensed Balance Sheets (Unaudited) as of June 30, 2013 and December 31, 2012	4
	Condensed Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2013 and 2012	5
	Condensed Statements of Comprehensive Loss (Unaudited) for the Three and Six Months Ended June 30, 2013 and 2012	6
	Condensed Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2013 and 2012	7
	Notes to Condensed Financial Statements (Unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4.	Controls and Procedures	28
Part II - Other Information
Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3.	Defaults Upon Senior Securities	29
Item 4.	Mine Safety Disclosures	29
Item 5	Other Information	29
Item 6.	Exhibits	30
	Signatures	31
	Exhibit Index	32

Part I — Financial Information

3

EXACT SCIENCES CORPORATION

Condensed Balance Sheets

(Amounts in thousands, except share data - unaudited)

	June 30,			December 31,
	2013			2012
ASSETS
Current Assets:
Cash and cash equivalents	$	21,518		$	13,345
Marketable securities	136,211			94,776
Prepaid expenses and other current assets	1,087			593
Total current assets	158,816			108,714
Property and Equipment, at cost:
Laboratory equipment	5,042			4,051
Office and computer equipment	1,396			824
Leasehold improvements	283			283
Furniture and fixtures	28			28
	6,749			5,186
Less—Accumulated depreciation	(2,355		)	(1,781		)
	4,394			3,405
	$	163,210		$	112,119
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	1,084		$	3,652
Accrued expenses	4,227			3,327
Capital lease obligation, current portion	342			333
Deferred license fees, current portion	2,366			4,143
Total current liabilities	8,019			11,455
Long-term debt	1,000			1,000
Long-term accrued interest	73			63
Capital lease obligation, less current portion	538			711
Deferred license fees, less current portion	—			295
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.01 par value Authorized—5,000,000 shares Issued and outstanding—no shares at June 30, 2013 and December 31, 2012	—			—
Common stock, $0.01 par value Authorized—100,000,000 shares Issued and outstanding—70,662,697 and 63,909,800 shares at June 30, 2013 and December 31, 2012	707			639
Additional paid-in capital	450,269			372,123
Other comprehensive income	17			78
Accumulated deficit	(297,413		)	(274,245		)
Total stockholders’ equity	153,580			98,595
	$	163,210		$	112,119

The accompanying notes are an integral part of these condensed financial statements.

4

EXACT SCIENCES CORPORATION

Condensed Statements of Operations

(Amounts in thousands, except per share data - unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
License fees	1,036			1,036			2,072			2,072
Operating expenses:
Research and development	6,457			12,202			13,983			21,201
General and administrative	3,628			2,393			6,276			4,538
Sales and marketing	3,302			1,331			5,061			1,925
	13,387			15,926			25,320			27,664
Loss from operations	(12,351		)	(14,890		)	(23,248		)	(25,592		)
Investment income	55			59			117			121
Interest expense	(18		)	(5		)	(37		)	(10		)
Net loss	$	(12,314	)	$	(14,836	)	$	(23,168	)	$	(25,481	)
Net loss per share—basic and diluted	$	(0.19	)	$	(0.26	)	$	(0.36	)	$	(0.45	)
Weighted average common shares outstanding—basic and diluted	64,699			57,037			64,270			56,877

The accompanying notes are an integral part of these condensed financial statements.

5

EXACT SCIENCES CORPORATION

Condensed Statements of Comprehensive Loss

(Amounts in thousands - unaudited)

	Three Months Ended June 30,						Six Months June 30,
	2013			2012			2013			2012
Net loss	$	(12,314	)	$	(14,836	)	$	(23,168	)	$	(25,481	)
Other comprehensive loss, net of tax
Unrealized holding gain (loss) on available-for-sale investments	(54		)	32			(61		)	67
Comprehensive loss	$	(12,368	)	$	(14,804	)	$	(23,229	)	$	(25,414	)

The accompanying notes are an integral part of these condensed financial statements.

6

EXACT SCIENCES CORPORATION

Condensed Statements of Cash Flows

(Amounts in thousands, except share data - unaudited)

	Six Months Ended June 30,
	2013			2012
Cash flows from operating activities:
Net loss	$	(23,168	)	$	(25,481	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	646			417
Loss on disposal of property and equipment	91			—
Stock-based compensation	3,811			2,459
Amortization of deferred license fees	(2,072		)	(2,072		)
Warrant licensing expense	—			152
Restricted stock licensing expense	—			1,000
Amortization of premium on short-term investments	270			220
Changes in assets and liabilities:
Prepaid expenses and other current assets	(494		)	(1,313		)
Accounts payable	(2,568		)	2
Accrued expenses	1,515			1,128
Accrued interest	10			10
Net cash used in operating activities	(21,959		)	(23,478		)
Cash flows from investing activities:
Purchases of marketable securities	(71,833		)	(33,764		)
Maturities of marketable securities	30,067			26,352
Purchases of property and equipment	(1,726		)	(729		)
Net cash used in investing activities	(43,492		)	(8,141		)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	73,302			—
Proceeds from exercise of common stock options and stock purchase plan	486			1,864
Payments on capital lease obligations	(164		)	—
Net cash provided by financing activities	73,624			1,864
Net increase (decrease) in cash and cash equivalents	8,173			(29,755		)
Cash and cash equivalents, beginning of period	13,345			35,781
Cash and cash equivalents, end of period	$	21,518		$	6,026
Supplemental disclosure of non-cash investing and financing activities:
Unrealized gain (loss) on available-for-sale investments	$	7		$	67
Issuance of 30,534 and 32,872 shares of common stock to fund the Company’s 401(k) matching contribution for 2012 and 2011, respectively	$	354		$	274
Conversion of accrued expenses into 34,442 and 34,336 shares of common stock in connection with the Company’s Employee Stock Purchase Plan for 2013 and 2012, respectively.	$	261		$	194

The accompanying notes are an integral part of these condensed financial statements.

7

EXACT SCIENCES CORPORATION

Notes to Condensed Financial Statements

(Unaudited)

(1) ORGANIZATION AND BASIS OF PRESENTATION

Organization

Exact Sciences Corporation (“Exact,” “we,” “us” or the “Company”) was incorporated in February 1995. Exact is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. The Company’s non-invasive stool-based DNA (sDNA) screening technology includes proprietary and patented methods that isolate and analyze human DNA present in stool to screen for the presence of colorectal pre-cancer and cancer.

Basis of Presentation

The accompanying condensed financial statements of the Company are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K (the “2012 Form 10-K”). These condensed financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair presentation of the results of operations have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2012 Form 10-K.  Management has evaluated subsequent events for disclosure or recognition in the accompanying financial statements up to the filing of this report.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers cash on hand, demand deposits in bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. The Company had no restricted cash at June 30, 2013 and December 31, 2012.

Marketable Securities

Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Marketable equity securities and debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the straight-line method, which approximates the effective interest method. Such amortization is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary on

8

available-for-sale securities are included in investment income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

At June 30, 2013 and December 31, 2012, the Company’s investments were comprised of fixed income investments and all were deemed available-for-sale. The objectives of the Company’s investment strategy are to provide liquidity and safety of principal while striving to achieve the highest rate of return consistent with these two objectives.  The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. All of the Company’s investments are considered current. There were no realized losses for the six months ended June 30, 2013 and June 30, 2012.  Realized gains were $2,760 and $2,528 for the six months ended June 30, 2013 and 2012, respectively. Unrealized gains or losses on investments are recorded in other comprehensive loss.

Available-for-sale securities at June 30, 2013 consist of the following:

	June 30, 2013
(In thousands)	Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
U.S. government agency securities	$	49,156	$	40	$	—		$	49,196
Corporate bonds	73,771		—		(35		)	73,736
Certificates of deposit	8,272		12		—			8,284
Commercial paper	4,995		—		—			4,995
Total available-for-sale securities	$	136,194	$	52	$	(35	)	$	136,211

Available-for-sale securities at December 31, 2012 consist of the following:

9

	December 31, 2012
(In thousands)	Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income		Estimated Fair Value
U.S. government agency securities	$	44,270	$	38	$	—	$	44,308
Corporate bonds	43,303		27		—		43,330
Certificates of deposit	5,926		13		—		5,939
Commercial paper	1,199		—		—		1,199
Total available-for-sale securities	$	94,698	$	78	$	—	$	94,776

Net Loss Per Share

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period.  Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:

	June 30,
(In thousands)	2013	2012
Shares issuable upon exercise of stock options	6,249	6,320
Shares issuable upon exercise of outstanding warrants (1)	155	325
Shares issuable upon the release of restricted stock awards	875	884
Shares issuable upon the vesting of restricted stock awards related to a licensing agreement	49	73
	7,328	7,602

(1)At June 30, 2013, represents warrants to purchase 80,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.  At June 30, 2012, represents warrants to purchase 250,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.

10

Revenue Recognition

License fees.   License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period. As more fully described in the 2012 Form 10-K, in connection with our January 2009 strategic transaction with Genzyme Corporation, Genzyme agreed to pay us a total of $18.5 million, of which $16.65 million was paid on January 27, 2009 and $1.85 million was subject to a holdback by Genzyme to satisfy certain potential indemnification obligations in exchange for the assignment and licensing of certain intellectual property to Genzyme. The Company’s on-going performance obligations to Genzyme under the Collaboration, License and Purchase Agreement (the “CLP Agreement”), as described below, including its obligation to deliver through licenses certain intellectual property improvements to Genzyme, if improvements are made during the initial five-year collaboration period, were deemed to be undelivered elements of the CLP Agreement on the date of closing. Accordingly, the Company deferred the initial $16.65 million in cash received at closing and is amortizing that up-front payment on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014. The Company received the first holdback amount of $962,000, which included accrued interest due, from Genzyme during the first quarter of 2010. The Company received the second holdback amount of $934,250, which included accrued interest due, from Genzyme during the third quarter of 2010.  The amounts were deferred and are being amortized on a straight-line basis into revenue over the remaining term of the collaboration at the time of receipt.

In addition, Genzyme purchased 3,000,000 shares of common stock on January 27, 2009 for $2.00 per share, representing a premium of $0.51 per share above the closing price of the Company’s common stock on that date of $1.49 per share. The aggregate premium paid by Genzyme over the closing price of the Company’s common stock on the date of the transaction of $1.53 million is deemed to be a part of the total consideration for the CLP Agreement. Accordingly, the Company deferred the aggregate $1.53 million premium and is amortizing that amount on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014.

The Company recognized approximately $1.0 million in license fee revenue in connection with the amortization of the up-front payments from Genzyme, during each of the three months ended June 30, 2013 and June 30, 2012. The Company recognized approximately $2.1 million in license fee revenue in connection with the amortization of up-front payments from Genzyme during each of the six months ended June 30, 2013 and June 30, 2012.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation in the financial statements and accompanying notes to the financial statements.

(3) MAYO LICENSE AGREEMENT

Overview

On June 11, 2009, the Company entered into a license agreement (the “License Agreement”) with MAYO Foundation for Medical Education and Research (“MAYO”). Under the License Agreement, MAYO granted the Company an exclusive, worldwide license within the field (the “Field”) of stool or blood based cancer diagnostics and screening (excluding a specified proteomic target) with regard to certain MAYO patents, and a non-exclusive worldwide license within the Field with regard to certain MAYO know-how. The licensed patents cover advances in sample processing, analytical testing and data analysis associated with non-invasive, stool-based DNA screening for colorectal cancer. Under the License Agreement, the Company assumes the obligation and expense of prosecuting and maintaining the licensed patents and is obligated to make commercially reasonable efforts to bring products covered by the license to market. Pursuant to the License Agreement, the Company granted MAYO two common stock purchase warrants with an exercise price of $1.90 per share covering 1,000,000 and 250,000 shares of common stock, respectively. The Company is also required to make payments to MAYO for up-front fees, fees once certain milestones are reached by the Company, and other payments as outlined in the License Agreement. In addition to the license to intellectual property owned by MAYO, the Company receives product development and research and development efforts from MAYO personnel. The Company determined that the payments made for intellectual property should not be capitalized as the future economic benefit derived from the transactions is uncertain. The Company is also obligated to make royalty payments to MAYO on potential future net sales of any products developed from the licensed technology.

11

Warrants

The warrants granted to MAYO were valued based on a Black-Scholes pricing model at the date of the grant. The warrants were granted with an exercise price of $1.90 per share of common stock. The grant to purchase 1,000,000 shares was immediately exercisable and the grant to purchase 250,000 shares vests and becomes exercisable over a four year period.

In March of 2010, MAYO partially exercised its warrant covering 1,000,000 shares by utilizing the cashless exercise provision contained in the warrant.  As a result of this exercise for a gross amount of 200,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 86,596 shares leaving it with a net amount of 113,404 shares.

In September of 2010, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant.  As a result of this exercise for a gross amount of 300,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 97,853 shares leaving it with a net amount of 202,147 shares.

In June of 2011, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 250,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 60,246 shares leaving it with a net amount of 189,754 shares.

In September of 2011, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 250,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 56,641 shares leaving it with a net amount of 193,359 shares. Following this exercise, the warrant covering 1,000,000 shares was fully exercised.

In January of 2013, MAYO partially exercised its warrant covering 250,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 85,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 14,008 shares leaving it with a net amount of 70,992 shares.

In June of 2013, MAYO partially exercised its warrant covering a remaining 165,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 85,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 12,765 shares leaving it with a net amount of 72,235 shares. The warrant now covers a total of 80,000 shares.

Royalty Payments

The Company will make royalty payments to MAYO based on a percentage of net sales of products developed from the licensed technology starting in the third year of the agreement.  Minimum royalty payments were $10,000 in 2012 and will be $25,000 per year through 2029, the year the last patent expires.

Other Payments

Other payments under the MAYO agreement include an upfront payment of $80,000, a milestone payment of $250,000 on the commencement of patient enrollment in FDA trials for the Company’s Cologuard pre-cancer and cancer screening test, and a $500,000 payment upon FDA approval of the Company’s Cologuard test.  The upfront payment of $80,000 was made in the third quarter of 2009 and expensed to research and development in the second quarter of 2009. The Company began enrollment in its FDA trial in June of 2011 and the milestone payment of $250,000 was made in June of 2011 and expensed to research and development in the second quarter of 2011.  It is uncertain as to when the FDA will approve the Company’s pre-cancer and cancer screening test. Therefore, the $500,000 milestone payment has not been recorded as a liability. The Company evaluates the status of the FDA trial at each reporting date to determine if a liability should be recorded for the milestone payment.

In addition, the Company is making payments to MAYO for research and development efforts.  During the three and six months ended June 30, 2013, the Company made payments of $0.3 million and $0.5 million, respectively. At June 30, 2013 the Company recorded an estimated liability in the amount of $0.5 million for research and development efforts.  During the three and six months ended June 30, 2012, the Company made payments of $0.2 million. At June 30, 2012 the Company recorded an estimated liability in the amount of $0.2 million for research and development efforts.

12

May 2012 Amendment

In May 2012 the Company expanded the relationship with MAYO through an amendment to the License Agreement. As part of the amendment, MAYO expanded the Company’s license to include all gastrointestinal cancers and diseases, and new cancer screening applications of stool- and blood-based testing. As consideration for the expanded license, the Company granted MAYO 97,466 shares of restricted stock, one quarter of which vested immediately, with the remainder to vest in three equal annual installments. The Company recognized $1.0 million in licensing expense during the twelve months ended December 31, 2012 in connection with the restricted stock grant due to the uncertainty in the license providing a future benefit.

As part of the amendment, the Company will also be responsible for making additional restricted stock grants to MAYO as certain milestones are met with respect to commercial launch of the Company’s second and third licensed products. Additionally, the Company will make milestone payments once certain sales levels are reached on the second and third licensed products. It is uncertain as to when these milestones will be met; therefore, the milestone payments have not been recorded as a liability. The Company evaluates the status of the milestone payments at each reporting date to determine if a liability should be recorded for the milestone payment.

(4) STOCK-BASED COMPENSATION

Stock-Based Compensation Plans

The Company maintains the 2010 Omnibus Long-Term Incentive Plan, the 2010 Employee Stock Purchase Plan,  the 2000 Stock Option and Incentive Plan and the 2000 Employee Stock Purchase Plan (collectively, the “Stock Plans”).

Stock-Based Compensation Expense

The Company recorded $2.8 million and $3.8 million in stock-based compensation expense during the three and six months ended June 30, 2013 in connection with the amortization of restricted stock and restricted stock unit awards, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors.   The Company recorded $1.5 million and $2.5 million in stock-based compensation expense during the three and six months ended June 30, 2012 in connection with the amortization of restricted stock and restricted stock unit awards, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees and non-employee directors.

In connection with the June 7, 2013 resignation of Laura Stoltenberg, the Company’s former Chief Commercial Officer, the Company modified the vesting of 100,000 shares of Ms. Stoltenberg’s previously unvested restricted stock units of which 41,250 of the restricted stock units vested upon the execution of the separation agreement, 10,000 will vest in March 2014, and the remaining 48,750 will vest in twenty-four equal monthly installments beginning in April 2014, subject to Ms. Stoltenberg’s continuing compliance with the terms of the separation agreement.  Ms. Stoltenberg forfeited all other unvested restricted stock units and stock option awards. It was determined that the continuing compliance and service to be provided to the Company under the separation agreement was not substantive and, as a result, the Company recorded the full value of the modified restricted stock units as additional stock-based compensation expense in the second quarter of 2013.

Determining Fair Value

Valuation and Recognition - The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model based on the assumptions in the table below. The estimated fair value of employee stock options is recognized to expense using the straight-line method over the vesting period.

Expected Term - The Company uses the simplified calculation of expected life, described in the SEC’s Staff Accounting Bulletins 107 and 110, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected life.  Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.

13

Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.

Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest.  A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates.  The Company’s forfeiture rate used in the six months ended June 30, 2013 was 2.76%. The Company’s forfeiture rate used in the six months ended June 30, 2012 was 1.38%.

The fair value of each restricted stock and restricted stock unit award is determined on the date of grant using the closing stock price on that day.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Option Plan Shares
Risk-free interest rates	0.94%		0.82%		0.94% - 1.15%		0.82% - 0.84%
Expected term (in years)	6		6		6		6
Expected volatility	82.9%		87.1%		82.9% - 84.0%		87.1% - 91.6%
Dividend yield	0%		0%		0%		0%
Weighted average fair value per share of options granted during the period	$	6.55	$	7.38	$	7.66	$	6.86
ESPP Shares
Risk-free interest rates	0.11% - 0.20%		0.19% - 0.27%		0.11% - 0.20%		0.19% - 0.27%
Expected term (in years)	0.5-2		0.5 - 2		0.5-2		0.5 - 2
Expected volatility	39.1% - 45.6%		39.6% - 54.9%		39.1% - 45.6%		39.6% - 54.9%
Dividend yield	0%		0%		0%		0%
Weighted average fair value per share of stock purchase rights granted during the period	$	2.80	$	3.47	$	2.80	$	3.47

14

Stock Option and Restricted Stock Activity

A summary of stock option activity under the Stock Plans during the six months ended June 30, 2013 is as follows:

					Weighted
			Weighted		Average
			Average		Remaining	Aggregate
			Exercise		Contractual	Intrinsic
Options	Shares		Price		Term (Years)	Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 2013	6,181,996		$	2.62	6.6	$	49,439
Granted	240,570		$	10.72
Exercised	(98,869	)	$	4.99
Forfeited	(74,250	)	$	8.67
Outstanding, June 30, 2013	6,249,447		$	2.83	6.2	$	69,266
Exercisable, June 30, 2013	5,205,858		$	1.84	5.8	$	62,849
Vested and expected to vest June 30, 2013	6,220,586		$	2.84	6.2	$	69,089

(1)The aggregate intrinsic value of options outstanding, exercisable and vested and expected to vest is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s common stock for options that had exercise prices that were lower than the $13.91 market price of the Company’s common stock at June 30, 2013.  The total intrinsic value of options exercised during the six months ended June 30, 2013 was $0.5 million. The total intrinsic value of options exercised during the six months ended June 30, 2012 was $3.4 million.

As of June 30, 2013, there was $11.0 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under all Stock Plans.  Total unrecognized compensation cost will be adjusted for future changes in forfeitures.  The Company expects to recognize that cost over a weighted average period of 2.85 years.

A summary of restricted stock activity under the Stock Plans during the six months ended June 30, 2013 is as follows:

15

			Weighted
	Restricted		Average Grant
	Shares		Date Fair Value
Outstanding, January 1, 2013	813,955		$	8.51
Granted	581,124		$	10.77
Released	(166,843	)	$	8.63
Forfeited	(352,836	)	$	9.45
Outstanding, June 30, 2013	875,400		$	9.61

During the first quarter of 2012, the Company granted a total of 262,500 restricted stock units to certain executives that would have vested based upon the satisfaction of certain service and performance conditions. These performance conditions were not met and the awards were forfeited during the first quarter of 2013. The expense recorded through December 31, 2012 for these awards totaling $0.6 million was reversed during the first quarter of 2013 due to the forfeiture.

During the first quarter of 2013, the Company granted a total of 180,750 restricted stock units to certain executives that will vest based upon the satisfaction of certain service and performance conditions.  The Company performed an evaluation of internal and external factors, and determined the number of shares that are most likely to vest based on the probability of which performance conditions will be met. The expense for the fair value of the awards that are expected to vest is being recognized ratably over the vesting period.

Warrants to purchase 75,000 shares of common stock were issued in connection with a consulting agreement in 2009. The warrants contain a performance condition and vest if the Company successfully receives FDA approval for its Cologuard test. The Company is uncertain if the performance conditions will be attained, and therefore no expense has been recorded on this warrant as of June 30, 2013. The exercise price of the warrant is $0.01.

(5) FAIR VALUE MEASUREMENTS

The FASB has issued authoritative guidance which requires that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions.  Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy.  The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs.  Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.  Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.

The three levels of the fair value hierarchy established are as follows:

Level 1	Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3	Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.

16

Fixed-income securities and mutual funds are valued using a third party pricing agency. The valuation is based on observable inputs including pricing for similar assets and other observable market factors. There has been no material change from period to period.  The estimated fair value of our long-term debt based on a market approach was approximately $1.0 million as of June 30, 2013 and December 31, 2012 and represent Level 2 measurements.  When determining the estimated fair value of our long-term debt, we used market-based risk measurements, such as credit risk.

The following table presents the Company’s fair value measurements as of June 30, 2013 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Amounts in the table are in thousands.

			Fair Value Measurement at June 30, 2013 Using:
			Quoted Prices in Active		Significant Other		Significant Unobservable
	Fair Value at		Markets for Identical Assets		Observable Inputs		Inputs
Description	June 30, 2013		(Level 1)		(Level 2)		(Level 3)
Cash and cash equivalents
Cash and money market	$	12,567	$	12,567	$	—	$	—
Certificates of deposit	8,951		—		8,951		—
Available-for-Sale
Marketable securities
U.S. government agency securities	49,196		—		49,196		—
Corporate bonds	73,736		—		73,736		—
Certificates of deposit	8,284		—		8,284		—
Commercial paper	4,995		—		4,995		—
Total	$	157,729	$	12,567	$	145,162	$	—

The following table presents the Company’s fair value measurements as of December 31, 2012 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall.  Amounts in the table are in thousands.

17

			Fair Value Measurement at December 31, 2012 Using:
			Quoted Prices in Active		Significant Other		Significant Unobservable
	Fair Value at		Markets for Identical Assets		Observable Inputs		Inputs
Description	December 31, 2012		(Level 1)		(Level 2)		(Level 3)
Cash and cash equivalents
Cash and money market	$	13,095	$	13,095	$	—	$	—
Corporate bonds	250		—		250		—
Available-for-Sale
Marketable securities
U.S. government agency securities	44,308		—		44,308		—
Certificates of deposit	5,939		—		5,939		—
Corporate bonds	43,330		—		43,330		—
Commercial paper	1,199		—		1,199		—
Total	$	108,121	$	13,095	$	95,026	$	—

As of June 30, 2013 and December 31, 2012 there were available-for-sale securities in a continuous unrealized loss position for less than twelve months where the total unrealized losses were $58,184 and $4,800 respectively. At June 30, 2013 and December 31, 2012 there were no available-for-sale securities in a continuous loss position for greater than twelve months.

The following summarizes contractual underlying maturities of the Company’s available-for-sale investments in debt securities at June 30, 2013 (in thousands):

	Cost		Fair Value
Due in one year or less	$	71,915	$	71,940
Due after one year through two years	64,279		64,271
	$	136,194	$	136,211

(6) EQUITY

On June 21, 2013, the Company completed an underwritten public offering of 6,325,000 shares of common stock at a price of $12.35 per share to the public. The Company received approximately $73.3 million of net proceeds from the offering, after deducting $4.8 million for the underwriting discount and other stock issuance costs paid by the Company.

18

(7) OPERATING LEASE

During the second quarter of 2013, the Company entered into a five year lease for a 29,000 square foot facility in Madison, Wisconsin to house our commercial lab operations. This lease contains periodic rent escalation adjustments and includes provisions for tenant improvements. The Company has two, five year options to extend the term of the lease.

Future minimum payments under the operating lease are as follows as of June 30, 2013. Amounts included in the table are in thousands.

Year Ending December 31,
2013	$	112
2014	676
2015	680
2016	684
2017	689
2018	578
Total lease obligations	$	3,419

(8) RELATED PARTY TRANSACTIONS

During the three months ended September 30, 2012, the Company entered into a one year consulting agreement with a non-employee director under which the director provides advisory services in support of the Company’s commercialization activities. In accordance with the agreement, the Company granted a restricted stock award for 4,873 shares of common stock that vests over one year, and will make cash payments totaling $60,000 over the one year term of the agreement.

(9) INCOME TAXES

The Company is subject to taxation in the U.S. and various state jurisdictions. All of the Company’s tax years are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses.

Under financial accounting standards, deferred tax assets or liabilities are computed based on the differences between the financial statement and income tax bases of assets and liabilities using the enacted tax rates. Deferred income tax expense or benefit represents the change in the deferred tax assets or liabilities from period to period.

A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, management has determined that a full valuation allowance at June 30, 2013 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact the Company’s effective tax rate.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.  At June 30, 2013 the Company had no unrecognized tax benefits, nor are there any tax positions where it is reasonably possible that the total

19

amounts of unrecognized tax benefits will significantly increase or decrease within the 12 months following June 30, 2013.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of the financial condition and results of operations of Exact Sciences Corporation should be read in conjunction with the condensed financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2012, which has been filed with the SEC (the “2012 Form 10-K”).

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections.  Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms.  Forward-looking statements in this Quarterly Report on Form 10-Q may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, timing and anticipated results of our pivotal clinical trial and our related FDA submissions, estimated markets for our products and expected revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy.  Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our 2012  Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.  We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.  Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Overview

Exact Sciences Corporation (“we,” “us,” “our” or the “Company”) is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. We have developed an accurate, non-invasive, patient friendly screening test to meet our primary goal of becoming the market leader for a diagnostic screening product for the early detection of colorectal pre-cancer and cancer.

Our strategic roadmap to achieve this goal includes the following key components:

· advance our product through U.S. Food and Drug Administration (FDA) clinical approval process;

· commercialize an FDA-approved product that detects colorectal pre-cancer and cancer; and

· secure favorable reimbursement for our product from payors.

Our Cologuard test is a non-invasive, stool-based DNA (sDNA) screening test designed to detect DNA markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, our test includes a protein marker to detect blood in the stool utilizing an antibody-based fecal immunochemical test (FIT).

Colorectal cancer is the second leading cause of cancer deaths in the United States and the leading cause of cancer deaths among nonsmokers.

20

It is widely accepted that colorectal cancer is among the most preventable, yet least prevented cancers. Colorectal cancer can take up to 10-15 years to progress from a pre-cancerous lesion to metastatic cancer and death. Patients who are diagnosed early in the progression of the disease—with pre-cancerous lesions or polyps, or early-stage cancer—are more likely to have a complete recovery and to be treated less expensively. Accordingly, the American Cancer Society recommends that all people age 50 and older undergo regular colorectal cancer screening. Of the more than 80 million people in the United States for whom routine colorectal cancer screening is recommended, nearly 47 percent have not been screened according to current guidelines. Poor compliance has meant that nearly two-thirds of colorectal cancer diagnoses are made in the disease’s late stages. The five-year survival rates for stages 3 and 4 are 67 percent and 12 percent, respectively.

We believe the large population of unscreened and inadequately screened patients represents a significant opportunity for a patient friendly screening test like ours. A powerful preventive tool that detects pre-cancerous polyps and early stage colorectal cancer could significantly reduce colorectal cancer deaths and the health care costs associated with the disease. Pre-cancerous polyps are present in approximately 6 percent of average risk people 50 years of age and older who undergo routine colorectal cancer screening.

The competitive advantages of sDNA screening provide a significant market opportunity. Assuming a 30-percent test adoption rate and a three-year screening interval, we estimate the potential U.S. market for sDNA screening to be more than $2 billion and we estimate the potential global market opportunity to be greater than $3 billion.

Our current focus is on seeking FDA approval for our Cologuard test. We believe obtaining FDA approval is important to building broad demand and successfully commercializing our sDNA colorectal cancer screening technology. We are also in the process of developing our strategy for the ultimate commercialization of our Cologuard test.

In November 2012 we completed enrollment for our pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada.  All patients provided a sample to be tested with our Cologuard test, and received a FIT test and a colonoscopy.

Preliminary, top-line data from the clinical trial showed that our Cologuard test demonstrated 92 percent sensitivity for the detection of colorectal cancer and 42 percent sensitivity for the detection of pre-cancerous polyps, including 66 percent sensitivity for polyps equal to or greater than 2 centimeters. The test achieved a specificity of 87 percent during the clinical trial.

The clinical trial achieved all of its endpoints.  The co-primary endpoints for the study were the sensitivity and specificity of the Cologuard screening test for colorectal adenocarcinoma.  The clinical trial included two sets of co-secondary endpoints.  The first included sensitivity and specificity of the test for advanced adenomas.  The second included superiority of Cologuard to FIT for cancer and advanced adenoma sensitivity.

Each patient result from the Cologuard test was compared to the patient’s colonoscopy result and the histopathologic diagnosis of any lesions that were discovered during colonoscopy and biopsied.  The study population included 65 cancer patients and 752 patients with pre-cancerous polyps.

We submitted the results of our clinical trial to the FDA through a three part submission of a manufacturing module, analytical module, and clinical module. The manufacturing module was submitted to the FDA in December 2012, the analytical module was submitted to the FDA in February 2013, and the clinical module was submitted to the FDA in June 2013. Our submission is currently under review by the FDA.

We believe that obtaining a favorable national coverage decision and a favorable reimbursement rate from the Centers for Medicare & Medicaid Services (CMS) for our Cologuard test will be a necessary element in achieving material commercial success.

With the goal of expediting receipt of a favorable coverage decision, we are working with CMS to coordinate the CMS coverage review with the FDA pre-market approval through a parallel review process. This program provides a pathway to a potential CMS national coverage determination shortly after an FDA approval, should it occur.

21

We plan to focus marketing efforts on primary care physicians who prescribe a high volume of fecal occult blood testing (FOBT) and FIT tests since this physician group has displayed a partiality for stool based screening methods. Six percent of primary care physician prescribers are responsible for 60% of FOBT/FIT volume.

We have generated limited operating revenues since inception and, as of June 30, 2013, we had an accumulated deficit of approximately $297.4 million. We expect to continue to incur losses for the next several years, and it is possible we may never achieve profitability.

2013 Priorities

Our top priorities for 2013 include completing the FDA submission and CMS coverage application for our Cologuard test. We submitted the final module of our FDA submission in June 2013. If for any reason the FDA does not approve our PMA or such approval is substantially delayed, our business and prospects would likely be materially adversely impacted. Likewise it would be a material adverse event for our business if we do not receive a positive national coverage decision and favorable reimbursement rate from CMS or if for any other reason we are unable to successfully commercialize our Cologuard test.

In 2013 we also plan to focus on building our manufacturing capacity which includes continuous improvements to our FDA compliant quality management system.

Another 2013 priority for us is establishing a CLIA certified lab facility to process Cologuard tests and provide patient results.

In addition, in 2013 we plan to work toward launch readiness through building and deploying a marketing team and continuing our outreach and education efforts to physicians, third party payors and advocates.

We also have identified a new opportunity for our sDNA colorectal cancer screening technology focused on the inflammatory bowel disease (IBD) patient population. We initiated an IBD clinical trial in the first quarter of 2013 that will focus on this specific patient group, and plan on enrolling approximately 300 IBD patients into the trial. Furthermore, we will work on developing enhancements to our Cologuard test and identifying and conducting research on other potential pipeline products targeting other cancers, such as esophageal and pancreatic cancer.

Financial Overview

Revenue.  Our revenue is comprised of the amortization of up-front license fees for the licensing of certain patent rights to Genzyme. We expect that license fees for 2013 will be consistent with amounts recorded in 2012.

Our Cost Structure.  Our selling, general and administrative expenses consist primarily of non-research personnel salaries, office expenses, professional fees, sales and marketing expenses incurred in support of our commercialization efforts and non-cash stock-based compensation.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, tax positions and stock-based compensation. We base our estimates on historical experience and on various other factors that are believed to be appropriate under the circumstances,

22

the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 of our financial statements included in the 2012 Form 10-K, we believe that the following accounting policies and judgments are most critical to aid in fully understanding and evaluating our reported financial results.

Revenue Recognition.

License fees.  License fees for the licensing of product rights on initiation of strategic agreements are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period.

In connection with our January 2009 strategic transaction with Genzyme Corporation, Genzyme agreed to pay us a total of $18.5 million, of which $16.65 million was paid on January 27, 2009 and $1.85 million was subject to a holdback by Genzyme to satisfy certain potential indemnification obligations in exchange for the assignment and licensing of certain intellectual property to Genzyme.  Our on-going performance obligations to Genzyme under the Collaboration, License and Purchase Agreement (the “CLP Agreement”), as described below, including our obligation to deliver certain intellectual property improvements to Genzyme, if improvements are made during the initial five-year collaboration period, were deemed to be undelivered elements of the CLP Agreement on the date of closing.  Accordingly, we deferred the initial $16.65 million in cash received at closing and are amortizing that up-front payment on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014.  We received the first holdback amount of $962,000, which included accrued interest due, from Genzyme during the first quarter of 2010 and the second holdback amount of $934,250, which included accrued interest, due from Genzyme during the third quarter of 2010.  The amounts were deferred and are being amortized on a straight-line basis into revenue over the remaining term of the collaboration at the time of receipt.

In addition, Genzyme purchased 3,000,000 shares of our common stock on January 27, 2009, for $2.00 per share, representing a premium of $0.51 per share above the closing price of our common stock on that date of $1.49 per share.  The aggregate premium paid by Genzyme over the closing price of our common stock on the date of the transaction of $1.53 million is deemed to be a part of the total consideration for the CLP Agreement.  Accordingly, we deferred the aggregate $1.53 million premium and are amortizing that amount on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014.

In total, we recognized approximately $1.0 million in license fee revenue in connection with the amortization of the up-front payments and holdback amounts from Genzyme during each of the three months ended June 30, 2013 and 2012 and approximately $2.1 million for each of the six months ended June 30, 2013 and 2012.

Stock-Based Compensation.  In accordance with GAAP, all stock-based payments, including grants of employee stock options, restricted stock and restricted stock units and shares purchased under an employee stock purchase plan (ESPP) (if certain parameters are not met), are recognized in the financial statements based on their fair values. The following assumptions are used in determining fair value for stock options, restricted stock and ESPP shares:

·Valuation and Recognition — The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. The estimated fair value of employee stock options is recognized to expense using the straight-line method over the vesting period.

·Expected Term - The Company uses the simplified calculation of expected life, described by the SEC’s Staff Accounting Bulletins 107 and 110, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term.  Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

·Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.

·Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining expected term.

23

·Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. The Company’s forfeiture rate used in the six months ended June 30, 2013 was 2.76%. The Company’s forfeiture rate used in the six months ended June 30, 2012 was 1.38%.

The fair value of each restricted stock award and restricted stock unit is determined on the date of grant using the closing stock price on that day. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model based on the assumptions in Note 4 to our condensed financial statements.

Results of Operations

Revenue.  Total revenue was $1.0 million for each of the three months ended June 30, 2013 and June 30, 2012. Total revenue was $2.1 million for each of the six months ended June 30, 2013 and June 30, 2012.  Total revenue is composed of the amortization of up-front technology license fee payments associated with our collaboration, license and purchase agreement with Genzyme. The unamortized Genzyme up-front payment and holdback amounts are being amortized on a straight-line basis over the initial Genzyme collaboration period, which ends in January 2014.

Research and development expenses.  Research and development expenses decreased to $6.5 million for the three months ended June 30, 2013 from $12.2 million for the three months ended June 30, 2012. Research and development expenses decreased to $14.0 million for the six months ended June 30, 2013 from $21.2 million for the six months ended June 30, 2012. This decrease was primarily due to a decrease in clinical trial costs, lab expenses, and professional fees due to our closing enrollment in the FDA clinical trial for our Cologuard test in November 2012.

	Three Months Ended June 30,
	2013		2012		Change
Personnel expenses	$	2.3	$	1.7	$	0.6
Professional fees	1.2		2.4		(1.2		)
Other research and development	0.8		0.8		—
Stock-based compensation	0.6		0.6		—
Lab expenses	0.5		1.5		(1.0		)
Research collaborations	0.5		0.3		0.2
Clinical trial expenses	0.4		3.7		(3.3		)
License and royalty fees	0.2		1.2		(1.0		)
Total research and development expenses	$	6.5	$	12.2	$	(5.7	)

24

	Six Months Ended June 30,
	2013		2012		Change
Personnel expenses	$	4.6	$	3.4	$	1.2
Professional fees	3.2		3.1		0.1
Other research and development	2.0		0.7		1.3
Stock-based compensation	1.1		1.1		—
Lab expenses	1.1		2.8		(1.7		)
Research collaborations	1.0		0.5		0.5
Clinical trial expenses	0.7		8.3		(7.6		)
License and royalty fees	0.3		1.3		(1.0		)
Total research and development expenses	$	14.0	$	21.2	$	(7.2	)

General and administrative expenses.  General and administrative expenses increased to $3.6 million for the three months ended June 30, 2013 compared to $2.4 million for the three months ended June 30, 2012. General and administrative expenses increased to $6.3 million for the six months ended June 30, 2013 compared to $4.5 million for the six months ended June 30, 2012. The increase in general and administrative expenses was primarily a result of increased legal and professional fees and other general and administrative expenses to support the overall growth of the Company.

	Three Months Ended June 30,
	2013		2012		Change
Legal and professional fees	$	1.3	$	0.6	$	0.7
Other general and administrative	0.9		0.6		0.3
Stock-based compensation	0.8		0.7		0.1
Personnel expenses	0.5		0.4		0.1
Facility costs	0.1		0.1		—
Total general and administrative expenses	$	3.6	$	2.4	$	1.2

	Six Months Ended June 30,
	2013		2012		Change
Legal and professional fees	$	2.2	$	1.2	$	1.0
Other general and administrative	1.8		1.1		0.7
Personnel expenses	1.0		0.9		0.1
Stock-based compensation	1.0		1.1		(0.1		)
Facility costs	0.3		0.2		0.1
Total general and administrative expenses	$	6.3	$	4.5	$	1.8

25

Sales and marketing expenses. Sales and marketing expenses increased to $3.3 million for the three months ended June 30, 2013, from $1.3 million for the three months ended June 30, 2012. Sales and marketing expenses increased to $5.1 million for the six months ended June 30, 2013 from $1.9 million for the six months ended June 30, 2012. The increase in sales and marketing expense was a result of hiring additional marketing personnel and increasing our efforts to prepare for the commercialization of our Cologuard test. The severance discussed in Note 4 to our condensed financial statements resulted in higher stock-based compensation and personnel costs in the three and six months ended June 30, 2013 compared to the same period in 2012.

	Three Months Ended June 30,
	2013		2012		Change
Stock-based compensation	$	1.4	$	0.2	$	1.2
Personnel expenses	1.1		0.5		0.6
Professional fees	0.6		0.6		—
Other sales and marketing	0.2		—		0.2
Total sales and marketing expenses	$	3.3	$	1.3	$	2.0

	Six Months Ended June 30,
	2013		2012		Change
Personnel expenses	$	1.9	$	0.7	$	1.2
Stock-based compensation	1.4		0.2		1.2
Professional fees	1.2		0.8		0.4
Other sales and marketing	0.6		0.2		0.4
Total sales and marketing expenses	$	5.1	$	1.9	$	3.2

Investment income.  Investment income decreased to $55,000 for the three months ended June 30, 2013 compared to $59,000 for the three months ended June 30, 2012.  Investment income decreased to $117,000 for the six months ended June 30, 2013 compared to $121,000 for the six months ended June 30, 2012. This is primarily due to a lower return on investment during the current year when compared to the same period in 2012.

Interest expense. Interest expense increased to $18,000 for the three months ended June 30, 2013 from $5,000 for the three months ended June 30, 2012.  Interested expense increased to $37,000 for the six months ended June 30, 2013 from $10,000 for the six months ended June 30, 2012. This increase is primarily due to interest expense recognized for our capital lease during the three and six months ended June 30, 2013 which was not in place in the prior period.

Liquidity and Capital Resources

We have financed our operations since inception primarily through private and public offerings of our common stock, cash received from LabCorp in connection with our license agreement with LabCorp, and cash received in January 2009 from Genzyme in connection with the Genzyme strategic transaction. As of June 30, 2013, we had

26

approximately $21.5 million in unrestricted cash and cash equivalents and approximately $136.2 million in marketable securities.

All of our investments in marketable securities are comprised of fixed income investments and all are deemed available-for-sale. The objectives of this portfolio are to provide liquidity and safety of principal while striving to achieve the highest rate of return, consistent with these two objectives. Our investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer.

Net cash used in operating activities was $22.0 million for the six months ended June 30, 2013 as compared to $23.5 million for the six months ended June 30, 2012.  The principal use of cash in operating activities for the six months ended June 30, 2013 was to fund our net loss which decreased from the six months ended June 30, 2012 primarily due to decreased research and development efforts as our clinical trial was completed in April 2013.

Net cash used by investing activities was $43.5 million for the six months ended June 30, 2013 as compared to  $8.1 million for the six months ended June 30, 2012.  The increase in cash used by investing activities for the six months ended June 30, 2013 compared to the same period in 2012 was primarily the result of the timing of purchases and maturities of marketable securities. Excluding the impact of purchases and maturities of marketable securities, net cash used in investing activities consisted of purchases of property and equipment of $1.7 million for the six months ended June 30, 2013 and $0.7 million for the same period in 2012. The increase in property and equipment purchases during the six months ended June 30, 2013 was primarily the result of increased laboratory equipment purchases and software costs as part of our commercialization efforts.

Net cash provided by financing activities was $73.6 million for the six months ended June 30, 2013, as compared to net cash provided by financing activities of $1.9 million for the six months ended June 30, 2012.  The increase in cash provided by financing activities for the six months ended June 30, 2013 was due to the receipt of $73.3 million of cash from our June 2013 common stock offering and $0.5 million of cash inflows from stock options exercises slightly offset by capital lease payments of $0.2 million compared to $1.9 million of cash inflows from stock option exercises for the same period in 2012.

We expect that cash and cash equivalents on hand at June 30, 2013 will be sufficient to fund our 2013 priorities and our current operations for at least the next twelve months, based on current operating plans. However, since we have no current sources of material ongoing revenue, we may need to raise additional capital to fund our strategic plan, the primary goal of which is obtaining FDA approval and successfully commercializing our Cologuard test. We have incurred significant expenditures in the process of completing the clinical trial for our Cologuard test which was completed in April 2013. We do not expect additional significant clinical costs related to obtaining approval for our Cologuard test. In addition, we are in the process of developing our strategy for the ultimate commercialization of our Cologuard test which will also take significant time and require significant expenditures. The timing of those expenditures is uncertain and depends in part upon the timeline for obtaining FDA approval.

Contractual Obligations

During the second quarter of 2013, we entered into a five year lease for a 29,000 square foot facility in Madison, Wisconsin to house our commercial lab operations. This lease contains periodic rent escalation adjustments and includes provisions for tenant improvements.

Future minimum payments under the operating lease are as follows. Amounts included in the table are in thousands.

27

Year Ending December 31,
2013	$	112
2014	676
2015	680
2016	684
2014	689
Thereafter	578
Total lease obligations	$	3,419

Off-Balance Sheet Arrangements

As of June 30, 2013, we had no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our exposure to market risk is principally confined to our cash, cash equivalents and marketable securities. We invest our cash, cash equivalents and marketable securities in securities of the U.S. government and its agencies and in investment-grade, highly liquid investments consisting of commercial paper, bank certificates of deposit and corporate bonds, which, as of June 30, 2013 were classified as available-for-sale. We place our cash equivalents and marketable securities with high-quality financial institutions, limit the amount of credit exposure to any one institution and have established investment guidelines relative to diversification and maturities designed to maintain safety and liquidity.

Based on a hypothetical ten percent adverse movement in interest rates, the potential losses in future earnings, fair value of risk-sensitive financial instruments, and cash flows are immaterial, although the actual effects may differ materially from the hypothetical analysis.

Item 4. Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15e promulgated under the Securities Exchange Act of 1934, as amended.  Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of June 30, 2013, our disclosure controls and procedures were effective.  Disclosure controls and procedures enable us to record, process, summarize and report information required to be included in our periodic SEC filings within the required time period.  Our disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed by us in the periodic reports filed with the SEC is accumulated and communicated to our management, including our principal executive, financial and accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

During the fiscal quarter covered by this report, there have been no significant changes in internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II - Other Information

Item 1.  Legal Proceedings

Not applicable.

28

Item 1A. Risk Factors

We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control.  In addition to the other information set forth in this report, the risks and uncertainties that we believe are most important for you to consider are discussed in Part I, “Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K.  There have been no material changes to the risk factors described in that report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In June 2009, we entered into a license agreement with MAYO Foundation for Medical Education and Research (“MAYO”) under which we acquired rights to use certain intellectual property.  As part of the license agreement, we granted MAYO two common stock purchase warrants with an exercise price of $1.90 per share covering 1,000,000 and 250,000 shares of common stock, respectively.

In January of 2013, MAYO partially exercised its warrant covering 250,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 85,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 14,008 shares leaving it with a net amount of 70,992 shares.

In June of 2013, MAYO partially exercised its warrant covering a remaining 165,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 85,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 12,765 shares leaving it with a net amount of 72,235 shares. The warrant now covers a total of 80,000 shares.

We believe that the offer and sale of the securities referenced were exempt from registration under the Securities Act by virtue of Section 4(2) of the Securities Act of 1933 (the “Securities Act”) and/or Regulation D promulgated thereunder as transactions not involving any public offering.  Use of this exemption is based on the following facts:

·      Neither we nor any person acting on our behalf solicited any offer to buy or sell securities by any form of general solicitation or advertising.

·      At the time of the purchase, MAYO was an accredited investor, as defined in Rule 501(a) of the Securities Act.

·      MAYO has had access to information regarding Exact and is knowledgeable about us and our business affairs.

In addition, we believe the issuance of shares on exercise of the warrants via cashless exercise was exempt from registration under the Securities Act by virtue of Section 3(a)(9) thereof inasmuch as such issuances involved the issuance of shares to an existing security holder in exchange for other securities where no commission or other remuneration was paid or given for soliciting such exchange.

Item 3.  Defaults Upon Senior Securities

Not applicable.

Item 4.  Mine Safety Disclosures

Not applicable.

Item 5.  Other Information

Not applicable.

29

Item 6.  Exhibits

The exhibits required to be filed as a part of this report are listed in the Exhibit Index.

30

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		EXACT SCIENCES CORPORATION
Date: August 2, 2013	By:	/s/ Kevin T. Conroy
		Kevin T. Conroy
		President and Chief Executive Officer (Principal Executive Officer)
Date: August 2, 2013	By:	/s/ Maneesh K. Arora
		Maneesh K. Arora
		Chief Operating Officer, Chief Financial Officer, and Secretary (Principal Financial Officer and Principal Accounting Officer)

31

EXHIBIT INDEX

Exhibit Number	Description
10.1	Separation Agreement and General Release between Laura S. Stoltenberg and Exact Sciences Corporation dated June 7, 2013 (previously filed as Exhibit 10.1 to our Report on Form 8-K filed on June 7, 2013, which is incorporated herein by reference)
10.2	Lease Agreement between The Alexander Company and Exact Sciences Laboratories, Inc. dated June 25, 2013.
31.1	Certification Pursuant to Rule 13(a)-14(a) or Rule 15d-14(a) of Securities Exchange Act of 1934.
31.2	Certification Pursuant to Rule 13(a)-14(a) or Rule 15d-14(a) of Securities Exchange Act of 1934.
32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	Interactive Data Files

32

EX-10.2

Exhibit 10.2

LEASE

Date:June 25, 2013

Landlord:Tech Building I, LLC

c/o The Alexander Company

145 E. Badger Road, Suite 200

Madison, WI  53713

Tenant:Exact Sciences Laboratories, Inc.

411 Charmany Dr.

Madison, WI  53719

1.BASIC TERMS.  The following terms shall have the meaning set forth in this Section unless specifically modified by other provisions of this Lease:

1.1Project:The land, building(s), improvements and appurtenants commonly known as Tech Building I and located at 145 East Badger Road Suite 100 as shown on attached Exhibit A.

1.2Building:The building situated in the Project in which the Premises are situated with a total rentable square footage equal to 54,731 sq ft.

1.3Premises:The space consisting of 28,994 rentable and 28,257 usable square feet as identified and described on attached Exhibit B located on the first (1st) floor of the Building. Per BOMA standards, Usable area shall mean the measured area where a tenant normally houses personnel and/or furniture. Rentable area shall mean the usable area of a tenant space with its associated share of floor common area and building common area.

1.4Common Areas:The areas of the Project not regularly and customarily leased for exclusive use of tenants, including, but not limited to, any entranceways and vestibules, common hallways and stairs, parking areas, driveways, walks and landscaped areas.

1.5Term:Approximately five (5) years commencing on the Commencement Date and terminating on the Termination Date (the “Initial Term”), subject to extension pursuant to Section 2.1.

1.6Commencement Date:Substantial completion of Tenant’s Work in accordance with Section 5 and Exhibit C of this Lease, which is anticipated to occur on November 1st, 2013, subject to adjustment as set forth in Section 2 below.

1.7Termination Date:October 31st, 2018, subject to adjustment as set forth in Section 2 below.

1.8Monthly Base Rent:See Exhibit I, subject to adjustment as set forth in Section 3.1 below.

1.9Initial Estimated Monthly Operating Charge: $7,610.93

1

1.10Tenant’s Proportionate Share: 52.9%.  Landlord reserves the right to equitably adjust Tenant’s share of the real estate taxes and insurance premiums included within the Operating Charges but only to the extent that such real estate taxes or insurance premiums increase after the Commencement Date solely as a result of the construction of Tenant’s Work and not due to any increase in the value of the Land or the value of the Building resulting from any factor other than the construction of Tenant’s Work.

1.11Permitted Use:  general office, research, and development with commercial CLIA lab, warehouse, and distribution, and subject to the use restrictions identified in Sections 6 and 6.1, any lawful use related or incidental thereto.

1.12Security Deposit:  none

1.13Guarantor(s):Exact Sciences Corporation

1.14Exhibits:A – Site Plan

B – Premises

C – Landlord’s and Tenant’s Work

D – Confirmation of Lease Term Agreement

E – Rules and Regulations

F – Novation Employment Reporting

G – Form ED-612 & Estimated Annual Employment Data

H – Assurances of Compliance w/Civil Rights and Other Legal

I  – Rent Schedule

2

2.DEMISE AND TERM.  Landlord leases the Premises to Tenant and Tenant leases the Premises described in Section 1.3 above from Landlord subject to the provisions of this Lease; provided, that any space in the Premises used for shafts, pipes, conduits, ducts, electrical or other utilities or Building facilities, as well as access thereto through the Premises for the purposes of installation, operation, maintenance, inspection, repair and replacement are reserved to Landlord and are excluded from the Premises. The Term of this Lease shall commence on the Commencement Date set forth in Section 1.6 and shall end on the Termination Date set forth in Section 1.7 unless adjusted or sooner terminated as provided herein.

Landlord acknowledges that the Commencement Date set forth in Section 1.6 is an anticipated date when Tenant shall substantially complete Tenant’s Work (as defined in Section 5) on account of construction of the Premises as set forth on Exhibit C attached hereto.  If Tenant shall be unable to substantially complete Tenant’s Work sufficient for occupancy and in accordance with Section 5 and Exhibit C of this Lease, the Commencement Date shall be delayed until substantial completion and the Termination Date shall be extended for an equal period plus the number of days necessary to end the Term on the last day of a month.  Notwithstanding the foregoing, under no circumstances will the Commencement Date be delayed past that date which is two hundred forty (240) days after the complete execution of this Lease and delivery of a copy to Tenant, except to the extent such delay is caused by Landlord, its agents, employees, or contractors.  Each party agrees, at the request of the other, to execute and deliver an instrument in substantially the form attached hereto as Exhibit D confirming the actual Commencement Date and the Termination Date when determined.

2.1Extension Option.  Tenant shall have two (2), five (5) year options to extend the Term of this Lease (the “Extension Option”) at the then escalated rate specified in Exhibit I attached hereto.  Each such option to extend the Term of this Lease (each, an “Extension Term”) shall be exercised by Tenant providing Landlord written notice that Tenant is extending the Term of this Lease.  To be effective said notice must be delivered to Landlord at least one hundred eighty (180) days prior to the expiration of the then current Term of the Lease.

3.RENT.  Beginning on the Commencement Date (but not earlier than November 1, 2013), Tenant agrees to pay to Landlord at Landlord’s address set forth on Page 1 of this Lease or such other place designated by Landlord, without prior demand or notice, the rent for the Premises consisting of Base Rent set forth in Section 3.1 and Operating Charges set forth in Section 3.2 and any other additional payments due under this Lease.  Upon execution of this Lease, Tenant shall pay to Landlord the sum of the amounts stated in Sections 1.8 and 1.9 for the first full month of the Term.  The obligation of Tenant to pay rent is hereby declared to be an independent covenant.

3.1Base Rent.  The amount specified in Exhibit I shall be payable in advance on the first day of each month during the Term (and any applicable Extension Term) beginning on the Commencement Date (but not earlier than November 1, 2013).  In the event the Term commences on other than the first day of a calendar month, the rent for such partial month shall be prorated based upon the actual number of days of the Term during such month.  The parties hereto agree that the Base Rent payable under the terms of this Lease shall be an absolute net return to Landlord for the Lease Term free from any expense, charge, deduction, offset or counterclaim by reason of any obligation of Landlord or any other reason and all of the provisions of this Lease shall be construed and interpreted to such end.

3.2Operating Charges.  Tenant shall pay to Landlord, as additional rent, Tenant’s Proportionate Share of Operating Charges as defined below.  Estimated amounts of such additional rent shall be paid in monthly installments in advance on the first day of each month during the Term.  The initial estimated payment of Tenant’s Proportionate Share of Operating Charges is set forth in Section 1.9.  From time to time during the Term, Landlord may notify Tenant in writing of any adjustment to the monthly installments to be paid by Tenant hereunder and thereafter Tenant shall make payments accordingly. Within sixty (60) days after the expiration of each calendar year or as soon thereafter as is reasonably practicable (but not later than 90 days after the expiration of each calendar year), Landlord shall notify Tenant of the actual Operating Charges for such calendar year and provide Tenant a written statement thereof in reasonable detail.  Within thirty (30) days after such notice, Tenant shall pay to Landlord or Landlord shall credit against the obligations of Tenant, as the case may be, the difference between the estimated payments made by Tenant

3

during the prior calendar year and the actual amount of Tenant’s Proportionate Share of Operating Charges as shown on such statement.  Tenant’s Proportionate Share of Operating Charges for the years in which the Term commences and ends shall be prorated based upon the number of days of the Term during such years.  Tenant’s obligation for Tenant’s Proportionate Share of Operating Charges through the Termination Date shall survive termination.

“Operating Charges” as used herein shall mean all sums expended or obligations incurred by Landlord with respect to the Project, whether or not now foreseen, determined on an accrual basis (including reasonably foreseeable expenditures not occurring annually), including, but not limited to, real estate taxes, special and/or area assessments and charges (or any substitutes hereafter collected by any governmental authority in lieu thereof or in addition thereto whether based on the value of the Project, cost of services, rent paid or received or otherwise) and any costs of seeking or obtaining a reduction or refund thereof; assessments and/or charges under any covenants and/or easements; salaries, fringe benefits and related costs of employees engaged on site in operation, maintenance or security; insurance covering hazards, casualties and potential losses; license, permit and inspection fees; management fees payable to third parties and/or to Landlord or its affiliates, provided the total of all such management fees shall not exceed three and one-half percent (3 ½%) of gross revenues for the Project; auditors’ fees and legal fees; internal accounting and administrative services; materials and supplies, including charges for telephone, telegraph, postage and supplies; repairs, maintenance and replacements respecting the Project, including costs of materials, supplies, tools and equipment used in connection therewith and including the seal coating and striping of parking areas, replanting of landscaped areas and replacing non-structural building components; costs incurred in connection with the operation, maintenance, repair, replacing, inspection and servicing (including maintenance contracts) of common electrical, plumbing, heating, air conditioning and mechanical equipment and the cost of materials, supplies, tools and equipment used in connection therewith; cost of services for the common areas including common electricity, gas, water and sewer and other utilities; and all other expenses and costs necessary or desirable to be incurred for the purpose of operating and maintaining the Project as an office complex, whether or not similar to the foregoing.  Notwithstanding anything in this Lease to the contrary, Operating Charges shall not include any of the following: (i) Landlord’s cost of utilities or other services, if any, separately sold by Landlord to tenants; (ii) costs incurred by Landlord for any alterations or tenant improvements for other tenants of the Project; (iii) costs incurred for maintenance, repairs, or replacements to Tenant’s interior improvements or mechanical, electrical, or plumbing improvements that are specific to a Tenant’s use and that Landlord bills directly to a tenant; (iv) depreciation of the Building and major components; (v) special assessments to the extent such assessments can be paid in installments and such installments are not then due; (vi) debt service, principal, or amortization on, or any charges related to, indebtedness of Landlord or mortgage encumbering the Project; (vii) leasing commissions; (viii) legal costs in connection with lease negotiations or the enforcement of leases; (ix) costs incurred due to violation of law or other violations by Landlord of any of the terms and conditions of this Lease; (x) all items and services of which Landlord receives reimbursement from Tenant or any other tenants outside of Operating Charges, or from third persons; (xi) advertising expenditures; (xii) repairs occasioned by fire, windstorm or other casualty and paid for through insurance or condemnation proceeds (exclusive of any deductibles); (xiii) salaries of officers and executives of Landlord other than the building manager and subordinate personnel engaged in the operation of the Project; (xiv) costs incurred for any items to the extent covered by a manufacturer’s, vendor’s, materialmen’s or contractor’s warranty to the extent that Landlord was actually reimbursed for same; (xv) cost of capital expenditures; (xvi) cost of any environmental remediation of the Project; (xvii) property management fees for the Project to the extent they exceed three and one-half percent (3 ½%) of the gross revenues of the Project; (xviii) cost incurred by Landlord in connection with any financing or sale of all or any portion of the Project; (ixx) costs representing amounts paid to an affiliate of Landlord for services or materials which are in excess of the amounts which would have been paid in the absence of such relationship; (xx) ground rent or any similar payments to a ground lessor; and (xxi) any other expense that under generally accepted accounting principles would not be considered a normal ownership, maintenance, management or operating expense for the Project. .

Tenant or its representative shall have the right to object Landlord’s statement and to demand an examination of Landlord’s books and records with respect to Operating Charges during normal business hours at any time within sixty (60) days following the furnishing by Landlord to Tenant of the aforementioned

4

statement. If Tenant shall not dispute any item or items shown on Landlord’s statement within sixty (60) days after such notice, Tenant shall be deemed to have approved such statement and shall be estopped from contesting such statement or the amount due.  If Tenant shall dispute any item or items included by Landlord in determining Operating Charges, Tenant shall nevertheless pay to Landlord in full the amount claimed by Landlord and shall not offset or withhold any payment while its dispute is pending.  If such dispute is not amicably settled between Landlord and Tenant within thirty (30) days after Tenant’s notice of the disputed Operating Charges, either party may during the fifteen (15) days after the expiration of such thirty (30) day period refer such disputed item or items to a reputable firm of independent certified public accountants designated by Landlord for resolution, and the decision of such firm shall be conclusive and binding upon Landlord and Tenant. In the event the decision is made in favor of Tenant, Landlord shall, within thirty (30) days after being notified the decision, reimburse the amount of such overpayment to Tenant, from the date of overpayment until the date of reimbursement at the Default Rate (as hereinafter defined).  The expenses involved in such determination shall be borne by the party against whom a decision is rendered by such accountants, provided that if more than one item is disputed and the decision shall be against each party in respect to any item or number of items disputed, then the expenses shall be apportioned according to the monetary value of the items decided against each party.

If during all or any portion of any calendar year the Project is not fully rented and occupied, Landlord shall make an appropriate adjustment (not to exceed 85% gross up adjustment) to any components of the Operating Charges which vary due to changes in occupancy levels (including, but not limited to, water, sanitary sewer, common utilities and common services in operating the Project) for such year, employing sound accounting and management principles, to determine the Operating Charges that would have been paid or incurred by Landlord had the Project been fully rented and occupied and the amount so determined shall be deemed to have been the Operating Charges for such year.  Notwithstanding anything to the contrary contained in this Lease, in the event that any part of the Project is exempted from real estate taxes, then Landlord may allocate the real estate taxes, assessments and charges payable with respect to the Project among the tenants occupying the taxable portion of the Project.

3.3Personal Property Taxes.  Tenant agrees to timely pay when due all personal property taxes, whether assessed against Landlord or Tenant, on Tenant’s furniture, equipment and other items of personal property owned by Tenant and located in or about the Premises.

3.4Late Charge.  Tenant acknowledges that late payment of rent (Base Rent or additional rental) involve additional costs to Landlord for collection and bookkeeping, and, in some instances could result in Landlord’s mortgagee imposing a late charge on Landlord, and, accordingly, Tenant agrees that, if rent (Base Rent or additional rental) due hereunder is not paid by the fifth day after it is due, then Tenant shall pay upon demand, as additional rent, a late charge equal to five percent (5%) of the amount required to be paid.  The foregoing provision for payment of a late charge shall not be construed to extend the date for payment of any sums required to be paid by Tenant hereunder or to relieve Tenant of its obligation to pay all such sums at the time or times herein stipulated, and neither the demand for, nor collection by, Landlord of such late charge shall be construed as a cure of Tenant’s default in the payment of rent.

4.ACCESS. Landlord shall provide Tenant with access to the Building and the Premises twenty-four (24) hours a day, seven (7) days a week, including but not limited to free access to the Building’s shared conference room with twenty-five (25) person seating capacity, projector, drop down screen, wet bar, audio system, WIFI, and conference phone facilities.  Tenant shall follow Landlord’s Conference Room Reservation policy. Landlord, at Landlord’s expense, shall initially furnish Tenant with a reasonable number of keys for the standard corridor doors serving the Premises and five (5) keys or access cards to provide access to the Building. Tenant shall have the right to use the prior tenant’s key fob access system and security system with cameras.

5.CONDITION OF PREMISES.  Within sixty (60) days of Lease signature, Landlord shall (i) demise the premises with a code-compliant, insulated, taped, and sealed demising wall in accordance with the plans approved by Tenant, (ii) ensure that all building systems (including but not limited to mechanical, electrical,

5

plumbing, and sprinkler) serving the demised Premises are in proper-working, code-compliant order, (iii) ensure the existing Premises, restrooms, common areas, and access paths are code and ADA compliant, and (iv) ensure the Building is supplied with 3 phase 480v, 800 electrical service (collectively, “Landlord’s Work”).  All of Landlord’s Work shall be done in a good and workmanlike manner in compliance with all building codes, laws and regulations applicable to the Building.  Tenant’s taking possession of the Premises shall be conclusive evidence that Tenant accepts the Premises and that they are in satisfactory condition except for any punch list of unsatisfactory items of which Tenant gives written notice to Landlord within ten (10) days after the Commencement Date which shall be corrected or repaired by Landlord within thirty (30) days after the Commencement Date.  Landlord and Tenant may mutually agree to allow Tenant to perform the Landlord’s Work, subject to complete reimbursement by Landlord to Tenant.  Tenant, at its sole cost and expense, shall perform all other alterations, improvements and other work necessary to prepare the Premises for Tenant’s use other than Landlord’s Work.  All such work shall be done in accordance with Section 14 below.  In the event that Landlord fails to deliver to Tenant the Premises with Landlord’s Work within sixty (60) days of Lease signature, Tenant shall have the right to terminate this Lease and in such case Tenant shall be relieved of all obligations and liabilities under this Lease.

Tenant shall substantially complete the construction of the improvements to the Premises as described on Exhibit C attached hereto (“Tenant’s Work”).  Tenant’s plans and specification for Tenant’s Work are subject to Landlord’s approval which must be received prior to the commencement of Tenant’s Work, such approval not to be unreasonably withheld, conditioned, or delayed.  All Tenant’s Work shall be done in a good and workmanlike manner in compliance with all building codes and regulations applicable to the Building.  Tenant’s taking possession of the Premises shall be conclusive evidence that Tenant accepts the Premises and that they are in satisfactory condition.  Any punch list of unsatisfactory items of which Landlord gives written notice to Tenant within ten (10) days after the Commencement Date shall be corrected or repaired by Tenant within ten (10) days of delivery of such notice.

Landlord shall provide Tenant with a tenant improvement allowance in the amount of TWO MILLION SEVEN HUNDRED THOUSAND AND NO/100 DOLLARS ($2,700,000.00) (“Tenant Improvement Allowance”) to pay a portion of Tenant’s build out costs, including but not limited to Tenant’s Work and all soft and hard costs related thereto.  The Tenant Improvement Allowance will be used only for the cost of improvements to the real property and not for the cost of personal property or other expenses except for the following costs: architectural costs; engineering costs;; cabling;; and any other costs expressly approved in writing by Landlord.  The Tenant Improvement Allowance will be released to Tenant in proportion to the total cost of Tenant’s improvements within thirty (30) days of receipt by Landlord of the construction invoices along with lien waivers for any previous invoice paid.  In addition to the Tenant Improvement Allowance, in the event Tenant performs the Landlord’s Work, Landlord shall reimburse Tenant for the cost associated with Landlord’s Work.  Should Tenant perform Landlord’s Work, the work must be bid and invoiced separately by Tenant’s contractor and approved by Landlord prior to the commencement of Landlord’s Work.  Landlord reserves the right to contract, and pay for, Landlord’s Work directly in which case Landlord shall not reimburse Tenant for Landlord’s Work, but shall actually perform such work. Any punch list of unsatisfactory items of which Landlord gives written notice to Tenant within ten (10) days after the Commencement Date shall be corrected or repaired by Tenant within ten (10) days of delivery of such notice. Nothing contained in this paragraph shall be deemed to relieve Landlord of its obligation under this Lease to construct and pay for Landlord’s Work.

6.USE.  The Premises shall be used only for the purpose set forth in Section 1.11 above (the “Permitted Use”) and for no other purposes.  Tenant shall not do or permit anything to be done in or about the Premises which in any way will obstruct or interfere with the rights of any other occupants of the Project, or use or allow the Premises to be used for any improper, immoral, unlawful or objectionable purpose or which could injure the reputation of the Project or otherwise violate any recorded covenant or restriction affecting the Project.  Tenant shall not cause or maintain or permit any nuisance or commit or suffer the commission of any waste in, on or about the Project.  Tenant shall not place a load upon any floor of the Premises which exceeds the floor load per square foot which such floor was designed to carry.  Tenant shall not cause or permit in or about the Premises any offensive odors or other odors objectionable to Landlord or other tenants or patrons of the Building.  Tenant expressly acknowledges that it shall be the sole responsibility of

6

Tenant to secure all necessary permits, licenses and approvals from all governmental authorities having jurisdiction for the operation of Tenant’s business.

6.1Use Restrictions.  Tenant certifies that it is not currently involved in the conduct of any of the following businesses (collectively “Excluded Businesses”) and covenants not to conduct any Excluded Business on the Premises either as a principal or ancillary business:

·Massage parlor

·Hot tub facility

·Suntan facility

·Country club

·Racetrack or other facility used for gambling

·Development or holding of intangibles for sale

·Private or commercial golf course

·Farming

·Sales, repairs, storage of service of mobile homes or contractors’ machinery and equipment

·Bulk fuel storage

·Fertilizer mixing or blending plants

·Slaughterhouses or meat processing plants

·Storage, repair and maintenance of carnival, concession and circus machinery and equipment

·Storage or processing of scrap or waste materials

·Adult book stores

·Check cashing services

·Pawn shops

Tenant further certifies that its principal business is not currently, and will not be during any period of the term of the Lease, the sale of alcoholic beverages for consumption off premises. Landlord hereby certifies that the Permitted Use does not violate any zoning ordinances affecting the Project, and that the only restrictive covenants affecting the Project are those contained in the Declaration of Protective Covenants for Novation Technology Campus.

7.COMPLIANCE WITH LAWS AND BUILDING RULES.

7.1Tenant shall, at its sole cost and expense, promptly comply with all laws, statutes, ordinances and governmental rules, regulations or requirements now or hereafter in force, and with the requirements of any insurance company insuring the Project, the local Board of Fire Underwriters or any similar body now or hereafter constituted relating to or affecting the condition, use or occupancy of the Premises.  Tenant shall not do or permit anything to be done on or about the Project or bring or keep anything therein which will in any way increase the cost of any insurance now or thereafter carried on the Project or any of its contents or that will invalidate any such insurance.  If Tenant installs any electrical equipment that overloads the electrical lines in the Premises, Tenant shall, at its own expense, make such changes as may be necessary to comply with the requirements of insurance underwriters and any governmental authority having jurisdiction.

7.2Tenant shall also comply with all rules and regulations to regulate the use, occupancy and operation of the Building which may from time to time be established by Landlord in writing (the “Building Rules”), and any modifications or amendments thereto provided they are applied uniformly to all tenants of the Building.  Landlord shall not be responsible to Tenant for the noncompliance by other tenants or occupants with the Building Rules.

7.3Except for costs and expenses to be borne by Tenant under Section 7.1, Landlord shall, at its sole cost and expense, promptly comply with all laws, statutes, ordinances and governmental rules, regulations or requirements now or hereafter in force, and with the requirements of any insurance company insuring the Project, the local Board of Fire Underwriters or any similar body now or hereafter constituted relating to or affecting the condition, use or occupancy of the Project.

7

8.ENVIRONMENTAL REQUIREMENTS.  Tenant shall comply with all applicable federal, state and local environmental laws, ordinances and all amendments thereto and rules and regulations implementing the same, together with all common law requirements, which relate to discharge, emissions, waste, nuisance, pollution control, hazardous substances and other environmental matters as the same shall be in existence during the Lease Term.  All of the foregoing laws, regulations and requirements are hereinafter referred to as “Environmental Laws”.  Tenant shall obtain all environmental licenses, permits, approvals, authorizations, exemptions, certificates and registrations (hereinafter collectively referred to as “Permits”) and make all applicable filings required of Tenant under the Environmental Laws required by Tenant to operate at the Premises.  The Permits and required filings shall be made available for inspection and copying by Landlord at Tenant’s offices upon reasonable notice and during business hours.  Tenant shall not cause or permit any flammable or explosive material, petroleum or petroleum by-products, contaminant, radioactive material, hazardous waste or material, toxic waste or material or any similar substance which is or may become regulated under any applicable federal, state or local law (hereinafter collectively referred to as “Hazardous Substances”) to be brought upon, kept or used in or about the Premises except in compliance with Environmental Laws and except for small quantities of such substances as is necessary in the ordinary course of Tenant’s business provided that Tenant shall handle, store, use and dispose of any such Hazardous Substance in compliance with all applicable laws and the highest standards prevailing in the industry for the storage and use of such substances or materials, in a manner which is safe and does not contaminate the Premises, and Tenant shall give Landlord written notice of the identity of such Hazardous Substances.  If any lender or governmental agency shall ever require testing to ascertain whether or not there has been any release of any Hazardous Substance due to Tenant’s failure to comply with the terms of this Lease, then the reasonable costs thereof shall be reimbursed by Tenant to Landlord upon demand as additional rent if such requirement applies to the Premises.  In addition, Tenant shall execute affidavits, representations and the like from time to time at Landlord’s request concerning Tenant’s best knowledge and belief regarding the presence of Hazardous Substances on the Premises.  Tenant hereby agrees to indemnify and hold Landlord harmless from any liability, claim or injury, including without limitation reasonable attorney fees and the cost of any required or necessary repair, cleanup, remediation or detoxification arising out of (i) the use, manufacture, handling, storage, disposal or release of any Hazardous Substances by Tenant, its agents and employees on, under or about the Premises, or (ii) an actual or alleged violation of Environmental Laws in connection with the occupancy of the Premises by Tenant or any occupant of the Premises or the operation of Tenant’s business on the Premises during the Lease Term, except to the extent any such violations are occasioned by the acts or negligence of Landlord, its agents, employees, customers or invitees.

Landlord represents and warrants that, to the best of its knowledge, the Building, the Premises, and the Project are not in violation of any Environmental Laws. Landlord hereby agrees to indemnify and hold Tenant harmless from any liability, claim or injury, including without limitation reasonable attorney fees and the cost of any required or necessary repair, cleanup, remediation or detoxification arising out of (i) the use, manufacture, handling, storage, disposal or release of any Hazardous Substances by Landlord, its agents and employees on, under or about the Project in violation of Environmental Laws, or (ii) Landlord’s breach of any provision or representation or warranty of this Section 8 applicable to Landlord.

The foregoing covenants and indemnification in this Section 8 shall survive the expiration of the Term of this Lease.

9.COMMON AREAS.  Tenant and its employees, customers and invitees shall have the reasonable nonexclusive right to use, in common with Landlord and the other tenants and occupants of the Project and their respective employees, customers and invitees and all others to whom Landlord has or may hereafter grant rights to use the same, the public portion of the Common Areas as may from time to time exist.  Landlord shall have the right to close any or all portions of the Common Areas to such extent as may, in Landlord’s opinion, be necessary to prevent a dedication thereof or the accrual of any rights to any person or the public therein, provided such closure shall not materially and adversely affect Tenant’s access to or use of the Premises or parking or signage rights under this Lease.  Landlord shall at all times have full control, management and direction of the Common Areas.  Tenant shall not cause or allow any storage of materials or equipment outside of the Premises on any of the Common Areas.  Landlord reserves the right

8

at any time and from time to time to reduce, increase, enclose or otherwise change the size, number, location, layout and nature of the Common Areas, to construct additional buildings and stories, to create additional rentable areas through use and/or enclosure of Common Areas, to close portions of the Common Areas for maintenance, repair or replacement, to place signs in the Common Areas and on the Building or in the Project, to change the name of the Project and to change the nature of the use of any portion of the Project, provided such actions shall not materially and adversely affect Tenant’s access to or use of the Premises or parking or signage rights under this Lease.

10.PARKING.  Tenant shall have the non-exclusive right to use up to seventy (70) parking stalls in the surface parking lot of the Building for Tenant, Tenant’s employees, customers and invitees.  Landlord reserves the right to regulate parking within the Common Areas, including the right to preclude Tenant from parking in certain parking spaces or requiring Tenant to use certain parking spaces, provided Tenant shall at all times have access to parking spaces located in reasonably proximity to the Building.  Tenant shall not permit vehicles to be abandoned or stored in the Project’s parking areas.  Tenant’s rights to parking shall be restricted to hours of operation of its business and so long as Tenant’s employees are working in the building while utilizing said parking spaces.

11.REPAIRS.  Landlord shall maintain the Common Areas and the exterior walls, roof, foundation, common HVAC and other systems (including but not limited to electrical, plumbing, sprinkler, and mechanical) of the building(s) in the Project, and the cost thereof shall be included in Operating Charges subject to the terms and conditions of Section 3.2; provided, however, that if any such repairs shall be occasioned by the negligence or willful misconduct of Tenant, its agents, employees, customers or invitees, or the particular nature of Tenant’s use of the Premises, Tenant shall be responsible for the entire cost of such repairs.  Except for the repairs Landlord is specifically obligated to make as set forth above or other terms of this Lease, Tenant shall, at its expense, during the Lease Term, make all other necessary repairs and replacements to the Premises, and keep and maintain the same in good condition and repair so that at the expiration of the Term, the Premises shall be surrendered to Landlord in good condition, ordinary wear and tear, casualty, and damage caused by Landlord, its agents, employees, or contractors excepted.  Tenant shall be responsible for repairing any damage to the Building caused by the installation or moving of Tenant’s furniture, equipment and personal property.  Tenant shall, at its expense, also repair or replace with glass of equal quality any broken or cracked plate or other glass in doors, windows  and elsewhere in or adjacent to the Premises, except for any damage caused by Landlord, its agents, employees, or contractors.  Tenant shall not defer any repairs or replacements to the Premises by reason of the anticipation of the expiration of the Term.  The surrender of the Premises upon the expiration or early termination of this Lease shall not relieve Tenant of the obligation to pay for all repairs or replacements to the Premises which Tenant was obligated to perform during the Lease Term, which obligation shall survive the expiration or early termination of this Lease.  Landlord, at Landlord’s option after at least thirty (30) days’ written notice to Tenant (except no prior notice shall be required in the event of emergency), may elect to perform all or part of the maintenance, repairs and servicing which is the obligation of the Tenant hereunder with respect to the Premises, in which event the cost thereof shall be at Landlord’s option either billed directly to and paid by Tenant as additional rent or included in Operating Charges.  Except as aforesaid, in the event that, at the request of Tenant, Landlord performs any maintenance, repairs or servicing of the Premises which is the obligation of Tenant hereunder, then Tenant shall pay Landlord directly therefor.

12.JANITORIAL SERVICES.  Tenant is solely responsible for Premises janitorial services as needed and shall pay all costs associated therewith.

13.UTILITIES; CABLING.  Tenant shall be responsible for obtaining all utility services in Tenant’s name for the Premises and shall pay for such services as and when payments are due. No discontinuance of any utility service shall relieve Tenant from performing any of its obligations under this Lease, and Landlord shall not be liable for any discontinuation in or failure of any utility service, and no such failure or discontinuation shall be deemed a constructive eviction, unless such discontinuance is caused by Landlord, its agents, employees, or contractors.  Tenant shall install separate utility meters for the Premises as part of Tenant’s Improvement Allowance and Tenant shall have its own control for the HVAC system.

9

During the entire Term of the Lease, Tenant shall have the exclusive right to use the existing 50 kw natural gas generator serving the Building (the “Existing Generator”). Tenant shall be responsible for connecting the Existing Generator to the electrical system serving the Premises and Landlord shall cooperate with Tenant to complete and maintain such connection. In addition, Tenant shall have the right to install an additional generator in a location near the Existing Generator, such exact location to be approved by Landlord and Tenant, and Tenant shall have the right to bring in additional electrical service to Premises if necessary for Tenant’s business operations.

Tenant shall have the right to install a water purifier system inside the Premises.

Tenant shall have the right to use the existing fiber optic cabling and service and the right to bring in its own fiber optic service for exclusive use in the Premises.

14.      ALTERATIONS.  Tenant shall not make any alterations, additions or improvements (“Alteration”) in, on or to the Premises or any part thereof without delivering to Landlord the plans and specifications therefor and obtaining the prior written consent of Landlord; provided, however, Tenant may make interior non-structural alterations which do not require a building permit costing not more than Fifteen Thousand and No/100 Dollars ($15,000.00) (“Cosmetic Changes”) in the aggregate during any calendar year to the Premises without obtaining Landlord’s consent.  Landlord’s consent to an Alteration may be granted or withheld in its commercially reasonable discretion or may be made contingent upon Tenant agreeing to such conditions relating thereto as Landlord may reasonably impose.  Any Alteration must be made at Tenant’s own cost and expense and in a good and workmanlike manner by contractor(s) reasonably approved by Landlord in accordance with the laws, ordinances and codes relating thereto and free from any claim or claims for construction liens, and Tenant shall indemnify and hold Landlord harmless from and against any and all claims, liens, costs and expenses on account of such work.  Upon completion of any Alteration requiring Landlord’s consent hereunder, Tenant shall provide Landlord with a copy of the as-built plans, blueprints and other items requested by Landlord for the same.

15.      SIGNS.       Landlord shall provide and install, at Tenant’s request, signage on the monument sign (the “Monument Signage”) and the northern face of the Building (the “Building Signage”) as reasonably agreed to by the parties and permitted by local code as well as vinyl signage on entry and rear doors (the “Suite Signage”) consistent with Landlord’s specifications.  The parties agree that the signage depicted on Exhibit J is an acceptable depiction of the Building Signage and the Landlord shall pursue the applicable approvals to permit the installation of such signage as depicted on Exhibit J and in the location depicted thereon.   Tenant shall not, without Landlord’s prior written consent, install, fix or use any other signs or other advertising or identifying media which is visible from the exterior of the Premises.  Landlord retains the right to change the location and/or appearance of any tenant’s signage at Landlord’s sole discretion; notwithstanding the foregoing, so long as Tenant occupies at least fifty percent (50%) of the rentable square footage of the Building during the Term, Landlord shall not modify or remove any of Tenant’s signage except in order to comply with local code. The Monument Signage and the Suite Signage shall be installed and maintained at Landlord’s sole cost and expense. The Building Signage shall be installed and maintained at Tenant’s sole cost and expense.

16.      LIENS.  Tenant shall not suffer or permit any liens under any construction lien law to be filed or recorded against the Premises or against the interest of either Landlord or Tenant therein.  If any such lien is filed or recorded, Tenant shall immediately cause such lien to be discharged of record.

17.      RIGHT OF ENTRY.  Landlord and its agents shall at all times after reasonable advance notice to Tenant have the right to enter the Premises to inspect the condition thereof, to supply any service to be provided by Landlord to Tenant hereunder, to show the Premises, and to alter, improve, or repair the Premises and any portion of the Building, provided Landlord shall not unreasonably interfere with Tenant’s business operations.  Tenant shall not add or change the locks to any doors of the Premises.  Tenant agrees to deposit or permit Landlord to deposit on Tenant’s behalf a key to the Premises in a lock box if required by and for the benefit of the local fire department.  Any entry to the Premises shall not under any circumstances be construed or deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an eviction, of Tenant or impose any liability on Landlord.  Nothing contained herein shall be deemed to

10

impose on Landlord any obligation or duty to make repairs or alterations to the Premises except as expressly provided in this Lease.  Notwithstanding anything in this Section 17 to the contrary, Landlord shall coordinate with Tenant prior to gaining access to sensitive scientific areas of the Premises. Landlord acknowledges that there may be medical records within the Premises and Landlord agrees that it is not authorized to view or disturb any such records. To the extent that Landlord comes into contact with any medical records, Landlord agrees to keep confidential any information obtained therefrom.

18.      INSURANCE.  Tenant shall, at its expense, obtain and carry at all times during the Term of this Lease (a) commercial general liability insurance including contractual liability coverage for the indemnification obligations of Tenant contained in this Lease covering injury to or death of persons and damage to property in an amount not less than $2,000,000.00 single limit per occurrence/$2,000,000.00 annual aggregate (or such higher amounts as Landlord shall from time to time reasonably determine); (b) fire insurance, with extended coverage, vandalism and malicious mischief and theft,  less a commercially reasonable deductible or coinsurance, covering the contents of the Premises and all alterations, additions and leasehold improvements made by or for Tenant in the amount of their full replacement value; and (c) such other insurance as may be reasonably  required from time to time by Landlord or any underlying lessor or mortgagee of the Project.  All of such policies of commercial general liability insurance shall be written by an insurance company or companies reasonably satisfactory to Landlord, shall name Landlord and Landlord’s lender as an additional insured, shall be written as primary policy coverage and not contributing with or in excess of any coverage which Landlord may carry, and shall contain a clause that the insurer will not cancel or change the insurance coverage without at least thirty (30) days prior written notice to Landlord.  A certificate of Tenant’s insurers in form satisfactory to Landlord evidencing such insurance shall be furnished to Landlord prior to the Commencement Date and at least thirty (30) days prior to the renewal date and at such other times as may be reasonably requested by Landlord.  Landlord may at any time and from time to time inspect and/or copy any and all insurance policies required to be procured by Tenant under this Lease.

Landlord shall maintain fire and extended coverage insurance on the Building, such policy(ies) to cover Landlord’s interest in the Building for not less than the full replacement value thereof, less a commercially reasonable deductible.  Such insurance shall cover Tenant’s Work and any Alterations and shall be maintained at the expense of Landlord, subject to reimbursement under Section 3.2.  Also, Landlord shall, at its own expense, maintain a policy or policies of comprehensive general liability insurance (occurrence coverage) with respect to its activities on the Project with the premiums thereon fully paid on or before the due date, issued by and binding upon an insurance company authorized to conduct such business in the State of Wisconsin.  Such comprehensive general liability insurance to be maintained by Landlord shall afford minimum protection of not less than $1,000,000 combined single limit coverage of bodily injury, property damage or combination thereof.

19.      WAIVER OF SUBROGATION.  Each party hereby expressly releases the other for liability it may have on account of any loss to the Premises or Building or contents of either due to fire or any peril included in the coverage of any applicable fire and extended coverage and material damage insurance, however caused, including such losses as may be due to the negligence of the other party, its agents or employees, but only to the extent of any amount recovered by reason of such insurance, and each party hereby waives any right of subrogation which might otherwise exist in or accrue to such party on account thereof, provided that such release of liability and waiver of the right of subrogation shall not be operative in any case where the effect thereof is to invalidate such insurance coverage under applicable state law (or increase the cost thereof, unless the other party reimburses the insured for any cost increase).  If Landlord or Tenant fails to maintain in force any insurance required by this Lease to be carried by it, then for purposes of this waiver of subrogation it shall be deemed to have been fully insured and to have recovered the entire amount of its loss.

20.      NON-LIABILITY OF LANDLORD.  Except for any claim arising from the willful misconduct or negligence of Landlord, its agents, employees, or contractors, then, only to the extent such claims are not covered by insurance, Landlord shall not be liable to Tenant, and Tenant hereby waives all claims against Landlord, for any injury or damage to any person or property in or about the Project resulting from the Project, Building or Premises, or any part thereof or any equipment thereof becoming out of repair; flooding

11

of basements or other areas; damages caused by sprinkling devices, air-conditioning apparatus, snow, frost, water leakage, steam, excessive heat or cold, falling plaster, broken glass, sewage, gas, odors or noise or the bursting or leaking of pipes or plumbing fixtures; any act or neglect of Landlord or of other tenants or occupants or employees in the Project; or any other thing or circumstance whatsoever, whether of a like nature or of a wholly different nature.  All property in or about the Project or in the Premises belonging to Tenant, its agents, employees or invitees shall be there at the risk of Tenant or other person only, and Landlord shall not be liable for damage thereto or theft, misappropriation or loss thereof except to the extent such shall damage, theft, misappropriation or loss is caused by the willful misconduct or negligence of Landlord, its agents, employees, or contractors.  If Landlord shall fail to perform any covenant or condition of this Lease upon Landlord’s part to be performed and, as a consequence of such default, Tenant shall recover a money judgment against Landlord, such judgment shall be satisfied only out of the proceeds of sale received upon execution of such judgment and levied thereon against the right, title and interest of Landlord in the Project and out of rents or other income from such property receivable by Landlord and Landlord shall not be personally liable for any deficiency.

21.      CASUALTY.  If the Premises are destroyed or damaged by fire or other casualty covered by a standard fire and extended coverage policy, then (unless this Lease is terminated by Landlord as hereinafter provided) Landlord shall proceed, after adjustment of such loss, to repair or restore the Premises to the condition immediately prior to the casualty, and such repairs and restoration shall be completed within two hundred seventy (270) days after the date of the casualty.  In no event shall Landlord be obligated to expend an amount in excess of the insurance proceeds available to Landlord for such repair or restoration.  If Landlord repairs or restores the Premises as provided herein, then Tenant shall repair and restore its furnishings, furniture and equipment to at least a condition equal to that prior to its damage, but only to the extent Tenant receives sufficient insurance proceeds for such repairs and restoration.  If the Premises or any part thereof shall be rendered untenantable by any destruction or damage, then a pro rata portion of the rent based upon the number of square feet of area in the Premises which are untenantable shall be abated until the Premises or such part thereof shall have been put in tenantable condition.  If, however, any destruction or damage to the Premises, Building or Project (regardless of whether or not the Premises are affected) is so extensive that Landlord, in its sole discretion, elects not to repair or restore the Premises, Building or Project, or the proceeds of insurance are not sufficient or available to fully pay the cost of repair or restoration, then Landlord may terminate this Lease effective as of the date of the damage by written notice to Tenant within ninety (90) days after the date of the casualty.  The provisions of this Section are subject to the rights of Landlord’s mortgagees, if any.

Notwithstanding anything in this Section 21 to the contrary, if by reason of any casualty, the Premises are rendered untenantable in some material portion, and the amount of time estimated by Landlord required to repair the damage using due diligence is in excess of two hundred seventy (270) days, then Tenant shall have the right to terminate this Lease by giving written notice of termination to Landlord within sixty (60) days after the date of casualty.  Also, if during the last twelve months of the Term (as same may be extended) there should be a casualty loss to the Premises or the Building to the extent of fifty percent (50%) or more of the replacement value thereof or if the Premises are rendered untenantable for the conduct of Tenant’s business operations, Tenant may, at its option, terminate this Lease by giving written notice of termination to Landlord within sixty (60) days after the date of the casualty.

22.      CONDEMNATION.  If all or substantially all of the Premises are sold to or taken by any public authority under its power of condemnation or the threat thereof, this Lease shall terminate as of the date possession shall be transferred to the acquiring authority, and the rent payable hereunder shall be apportioned accordingly.  If any material part of the Project is sold or taken (whether or not the Premises are affected), Landlord shall have the right to terminate this Lease as of the date possession is transferred to the acquiring authority, upon giving written notice thereof to Tenant, and the rent payable hereunder shall be apportioned accordingly.  Upon any taking of less than substantially all of the Premises, this Lease shall continue in force as to the part of the Premises not taken, and the rent payable thereafter shall be reduced in proportion to the amount of total floor area of the Premises taken.  In the event of any such taking, Landlord, upon receipt and to the extent of the award in condemnation or proceeds of sale, shall, unless this Lease has been terminated, make necessary repairs and restorations  to restore the Premises remaining to as near its former condition as circumstances will permit and to rebuild or restore the remainder of the

12

Premises to the approximate condition in which they existed at the time of such taking.  In any event, all damages awarded by or amounts paid by the acquiring authority for any such taking, whether for the whole or a part of the Premises or the Building, Common Areas or Project, shall belong to and be the sole property of Landlord whether such damages are awarded as compensation for loss of, or diminution in value to, the leasehold or the fee thereof; provided, however, Tenant shall have the right to pursue such claim or claims as Tenant may have legally for the fair market value of Tenant’s Work actually paid for by Tenant (and not paid for by Landlord or from the Tenant Improvement Allowance), its leasehold estate, relocation expenses, interruption of business and such items which do not reduce the award or proceeds of sale payable to Landlord.  In the event that this Lease is terminated as hereinabove provided, Tenant shall not have any claim against Landlord for the value of the unexpired term hereof.  The provisions of this Paragraph are subject to the rights of Landlord’s mortgagees, if any.

If a substantial portion of the Premises or the Building is taken under the power of condemnation (including any conveyance made in lieu thereof) or if any taking of the Premises, Building or any common areas of or serving the Building shall materially impair the normal operation of Tenant’s business, then Tenant shall have the right to terminate this Lease by giving written notice of such termination within thirty (30) days after such taking.

23.  ASSIGNMENT AND SUBLETTING.  Tenant shall not assign, pledge, mortgage or otherwise transfer or encumber this Lease or sublet any part or all of the Premises and shall not permit any use of any part of the Premises by any other party, or any transfer of as interest in the Premises by operation of law without Landlord’s consent, such consent not to be unreasonably withheld, delayed, or denied; provided, however, and notwithstanding anything to the contrary contained herein, Tenant shall be permitted to assign this Lease or sublet all or any portion of the Premises, without the consent of Landlord, (i) to an entity into which Tenant may merge, which Tenant may acquire, or which Tenant may consolidate with, (ii) to any parent or subsidiary of Tenant, or (iii) to a purchaser of substantially all of Tenant’s assets or a controlling interest in the outstanding voting stock of Tenant (iv) to any entity which is affiliated with Tenant or any entity controlling, controlled by, or under common control with Tenant..  The following shall be deemed to be an assignment of this Lease within the meaning of this Paragraph: (a) the sale, issuance or transfer of any voting stock of Tenant (if Tenant be a nonpublic corporation or if Tenant is a public corporation and such sale, issuance or transfer results in Tenant becoming a nonpublic corporation) which results in a change in voting control of Tenant; (b) the sale, issuance or transfer of any partnership interest in Tenant if Tenant be a partnership; (c) the change or conversion of a general or limited partnership to a limited liability company, limited liability partnership or any other entity which possesses the characteristics of limited liability; (d) the sale, issuance or transfer of any beneficial interest in Tenant if Tenant be a trust; and (e) the death or incapacity of Tenant if Tenant be a natural person.  Without waiving Landlord’s right hereunder to declare a default in the event of an assignment of this Lease or a subletting of the Premises or any part thereof or occupancy of the Premises by anyone other than Tenant, Landlord may collect from the assignee, sublessee or occupant, any rental and other charges herein required, but such collection by Landlord shall not be deemed an acceptance of the assignee, sublessee or occupancy, nor a release of Tenant from the performance by Tenant of this Lease.  Further, Tenant at all times and under all circumstances shall remain liable to Landlord for the payment of rent due and to become due and the performance of all other obligations of Tenant hereunder for the term hereof.  Tenant shall pay to Landlord, as additional rent, any costs and expenses including reasonable attorney fees incurred by Landlord in connection with any proposed or purported assignment, sublease or other transfer requiring Landlord’s consent, such total amount not to exceed $1,500.

All option rights, extension rights, renewal rights, expansion rights, and rights of first refusal will flow through to all assignees or subtenants.

24.      DEFAULT.  If (a) Tenant shall fail to pay the rent or any charge due hereunder within five (5) days after written notice from Landlord, or (b) Tenant shall fail to perform any of the other covenants or conditions herein contained on the part of Tenant, and such default shall continue for thirty (30) days after written notice thereof shall have been given to Tenant (except that such thirty (30) day period shall be automatically extended for an additional period of time reasonably necessary to cure such default, if such default cannot be cured within such thirty (30) day period and provided Tenant commences the process of curing such

13

default within said thirty (30) day period and continuously and diligently prosecutes such cure to completion, and except that, if Tenant fails to timely deliver any subordination instruments under Section 30 or estoppel certificates under Section 32, no additional grace period shall be allowed beyond the ten (10) days referred to in such sections), or (c) if this Lease shall, by act of Tenant or by operation of law or otherwise, pass to any party other than Tenant in violation of this Lease, or (d) intentionally deleted, or (e) Tenant or any guarantor of this Lease shall become insolvent or bankrupt or make an assignment for the benefit of creditors, or (f) a receiver or trustee of Tenant’s property or that of any guarantor of this Lease shall be appointed and such receiver or trustee, as the case may be, shall not be discharged within thirty (30) days after such appointment, or (g) an execution or attachment is levied against Tenant’s property or that of any guarantor of this Lease and is not bonded or otherwise removed within thirty (30) days, Landlord may, upon notice to Tenant, recover possession of and reenter the Premises without affecting Tenant’s liability for past rent and other charges due or future rent and other charges to accrue hereunder.  In the event of any such default beyond any applicable notice and cure period, Landlord shall be entitled to recover from Tenant, in addition to rent and other charges equivalent to rent, all other damages sustained by Landlord on account of the breach of this Lease, including, but not limited to, reasonable the costs, expenses and attorney fees incurred by Landlord in enforcing the terms and provisions hereof and in reentering and recovering possession of the Premises and for the cost of repairs, alterations and brokerage and attorney fees connected with the reletting of the Premises.  Further, at the election of Landlord, Landlord shall have the right to declare this Lease terminated and cancelled, without any further rights or obligations on the part of Landlord or Tenant (other than Tenant’s obligation for rent and other charges due and owing through the date of termination), so that Landlord may relet the Premises without any right on the part of Tenant to any credit or payment resulting from any reletting of the Premises.  In case of a default under this Lease beyond any applicable notice and cure period, Landlord may, in addition to terminating this Lease, or in lieu thereof, pursue such other remedy or combination or remedies and recover such other damages for breach of tenancy and/or contract as available at law or otherwise.

Landlord may, but shall not be obligated to, cure any default by Tenant (specifically including, but not by way of limitation, Tenant’s failure to obtain insurance, make repairs, or satisfy lien claims) and whenever Landlord so elects, all reasonable costs and expenses paid by Landlord in curing such default, including without limitation attorney fees, shall be payable to Landlord as additional rent due on demand, together with interest at the rate provided in Section 26 below from the date of the advance to the date of repayment by Tenant to Landlord.

A waiver by Landlord of a breach or default by Tenant under the terms and conditions of this Lease shall not be construed to be a waiver of any subsequent breach or default nor of any other term or condition of this Lease, and the failure of Landlord to assert any breach or to declare a default by Tenant shall not be construed to constitute a waiver thereof so long as such breach or default continues unremedied.

No receipt of money by Landlord from Tenant after the expiration or termination of this Lease or after the service of any notice or after the commencement of any suit, or after final judgment for possession of the Premises shall reinstate, continue or extend the Term of this Lease or affect any such notice, demand or suit.

Notwithstanding anything contained herein to the contrary, following an default that is not timely cured under this Section 24, Landlord shall be obligated to use commercially reasonable efforts to mitigate all damages which may accrue hereunder, at law or in equity as a result of any default or breach by Tenant of any of the terms of this Lease.

25.      COSTS AND ATTORNEY FEES.  Tenant shall pay all costs, expenses and reasonable attorney fees that may be incurred or paid by Landlord in enforcing the covenants and agreements of this Lease, whether or not litigation is commenced.

26.      INTEREST.  Any amount due from Tenant to Landlord hereunder which is not paid when due after any applicable notice and cure period shall bear interest at an annual rate equal to the greater of (i) five percent (5%) per annum in excess of the prime rate of interest announced, from time to time, by The Wall Street Journal, or, if such publication ceases publication, by another reputable financial periodical selected

14

by Landlord, or (ii) twelve percent (12%) per annum (but in no event shall such rate of interest exceed the maximum rate of interest permitted to be charged by law) (the “Default Rate”) from the date due until paid, compounded monthly, but the payment of such interest shall not excuse or cure any default by Tenant under this Lease.

27.      SURRENDER.  Upon the termination of this Lease, by expiration or otherwise, Tenant shall peaceably surrender the Premises to Landlord broom-clean and in good condition and repair consistent with Tenant’s duty to make repairs as provided herein.  All Alterations and decorations made to the Premises by Tenant shall remain and be the property of the Landlord unless Landlord shall require Tenant, at Tenant’s expense, to remove any or all thereof and repair the damage caused by such removal, such notice of removal of Alterations to be given to Tenant at the time such Alterations are approved by Landlord.  All furniture, equipment and unattached movable personal property owned by Tenant may (and upon Landlord’s request shall) be removed from the Premises by Tenant no later than the termination date, and Tenant shall repair any and all damage caused by such removal.  If the Premises are not surrendered upon the termination of this Lease as set forth herein, Tenant shall indemnify Landlord against all loss or liability actually incurred by Landlord resulting solely from delay by Tenant in so surrendering the Premises including, without limitation, any prevailing claim made by any succeeding tenant founded on such delay.  Tenant shall also surrender all keys to the Premises and shall inform Landlord of combinations in any locks, safes and vaults, if any, in the Premises.

28.      HOLDOVER.  In the event Tenant remains in possession of the Premises after the expiration of this Lease with the consent of Landlord and without the execution of a new lease, it shall be deemed to be occupying said premises as a tenant from month-to-month, subject to all of the conditions, provisions and obligations of this Lease insofar as the same are applicable to a month-to-month tenancy until the termination of such tenancy and the Base Rent shall be at 150% of the latest Base Rent applicable under this Lease.

29.      TRANSFER BY LANDLORD.  In the event of a sale or conveyance by Landlord of the Building to a party that assumes in writing Landlord’s obligations under the Lease, the same shall operate to release Landlord from any future liability upon any of the covenants or conditions herein contained, and in such event Tenant agrees to look solely to the successor in interest of Landlord in and to this Lease.  This Lease shall not be affected by any such sale or conveyance, and Tenant agrees to attorn to the purchaser or grantee, which shall be obligated on this Lease only so long as it is the owner of Landlord’s interest in and to this Lease.

30.      SUBORDINATION.  Subject to and only upon execution by Tenant and the relevant lienholder of a subordination, nondisturbance and attornment agreement in form and content reasonably acceptable to Tenant and such lienholder, this Lease is and shall be subject and subordinate at all times to all ground or underlying leases which now exist or may hereafter be executed affecting the Building and to the lien of any mortgages now or hereafter placed on or against the Building, or on or against Landlord’s interest or estate therein, and including all extensions, renewals, amendments and supplements to any such lease or mortgage.  Tenant covenants and agrees to execute and deliver to Landlord, within ten (10) days after request therefor from Landlord, such further instruments evidencing such subordination of this Lease to any ground or underlying leases and to the lien of any such mortgages as may be required by Landlord provided that any lessor under any such ground or underlying lease or the holder of any mortgage has agreed not to terminate or disturb Tenant’s right to use and occupy the Premises pursuant to the terms of this Lease so long as Tenant is not in default hereunder beyond any applicable notice and cure period.  Failure of Tenant to execute and deliver such instrument within such ten (10) day period shall constitute a breach of this Lease.  Further, Tenant hereby irrevocably appoints Landlord as attorney-in-fact for Tenant with full power and authority to execute and deliver in the name of Tenant any such instrument if Tenant fails to execute and deliver the same within the time period as aforesaid.  Notwithstanding anything herein above contained in this Section, in the event the holder of any mortgage shall at any time elect to have this Lease constitute a prior and superior lien to its mortgage, then and in such event, upon any such holder notifying Tenant to that effect in writing, this Lease shall be deemed prior and superior in lien to such mortgage, whether this Lease is dated prior to or subsequent to the date of such mortgage.

15

Landlord will deliver to Tenant a non-disturbance agreement from any existing or future mortgagee or ground landlord of Landlord in favor of Tenant and in form and content reasonably acceptable to Tenant and such mortgagee or ground landlord, as applicable.

31.      MODIFICATIONS.  Tenant agrees to execute any modification of this Lease which may be required by a lender as a condition to making a first mortgage loan on the Project; provided that no such modification shall alter the rent or term provided herein, or materially reduce the economic value hereof to Tenant, or materially affect Tenant’s business operations in the Premises, or increase Tenant’s financial obligations under this Lease.  Tenant agrees to complete and promptly return any estoppel certificates that may be required in connection with any mortgage loan on the Building.  Upon request (not more than two times in any calendar year), Tenant shall furnish Landlord and its lender a copy of the current annual financial statement, provided Landlord and its lender agree to keep such financial information confidential.

32.      ESTOPPEL CERTIFICATES.  Tenant agrees that at any time and from time to time within ten (10) days after request from Landlord or one of Landlord’s mortgagees, Tenant shall execute, acknowledge and deliver to Landlord a statement in writing certifying (a) that this Lease is unmodified and in full force and effect (or if there have been modifications, specifying the same), and (b) the dates to which the rent and other charges have been paid, and (c) that, so far as the Tenant knows, Landlord is not in default under any provisions of this Lease (or if Tenant knows of any such default, specifying the same) and (d) such other matters as Landlord or Landlord’s mortgagee may reasonably require.  It is intended that any such statement may be relied upon by any person proposing to acquire Landlord’s interest in this Lease or any prospective mortgagee of, or assignee of any mortgage upon, such interest.

33.      NOTICES.  All notices and demands which may or are required to be given by either party to the other hereunder shall be in writing, and delivered in person or sent by either United States certified mail, return receipt requested, postage prepaid or by Federal Express or other nationally recognized overnight delivery service.  Notices and demands to Tenant shall be addressed to it at the address indicated on Page 1 of this Lease or to such other place as the Tenant may from time to time designate in a written notice to the Landlord.  Notices and demands to the Landlord shall be addressed to it at the address indicated on Page 1 of this Lease, or to such other place as Landlord may from time to time designate in a written notice to the Tenant.

34.      EXECUTION.  The submission of this document for examination does not constitute an offer to lease, or a reservation of, or option for, the Premises and this document becomes effective and binding only upon the execution and delivery hereof by both Landlord and Tenant.  Tenant confirms that Landlord has made no representations or promises with respect to the Premises or the making or entry into of this Lease except as are expressly set forth herein, and agrees that no claim or liability shall be asserted by Tenant against Landlord for, and Landlord shall not be liable by reason of, breach of any representations or promises not expressly stated in this Lease.  This Lease can be modified or altered only by agreement in writing between Landlord and Tenant.  Upon Tenant’s request, Landlord shall execute and deliver to Tenant a memorandum of this Lease in recordable form and Tenant shall have the right to record such memorandum at Tenant’s sole cost and expense.

35.      BINDING EFFECT.  The covenants, agreements and obligations herein contained, except as herein otherwise specifically provided, shall extend to, bind and inure to the benefit of the parties hereto and their respective personal representatives, heirs, successors and assigns (but in the case of assigns only to the extent that assignment is permitted hereunder).  No third party, other than such successors and assigns, shall be entitled to enforce any or all of the terms of this Lease or shall have rights hereunder whatsoever.

36.      INTENTIONALLY OMITTED.

37.      INTERPRETATION.  The laws of the State of Wisconsin shall govern the validity, performance and enforcement of this Lease.  The invalidity or unenforceability of any provision of this Lease shall not affect or impair any other provision.  Whenever the singular number is used, the same shall include the plural, and the masculine gender shall include the feminine and neuter genders.  The captions appearing in this Lease

16

are inserted only as a matter of convenience and in no way define, limit, construe or describe the scope or intent of such sections or paragraphs of this Lease nor in any way affect this Lease.

38.      FORCE MAJEURE.  In the event that Landlord or Tenant shall be delayed or hindered in or prevented from the performance of any act required hereunder by reason of strikes, lockouts, labor troubles, inability to procure materials, failure of power, restrictive governmental laws, regulations, orders or decrees, riots, insurrection, war, acts of God, inclement weather, or other reason beyond such party’s reasonable control, then performance of such act shall be excused for the period of the delay and the period for the performance of any such act shall be extended for a period equivalent to the period of such delay.

39.      AUTHORITY.  If Tenant is a corporation or limited liability company or other entity, each individual executing this Lease on behalf of Tenant represents and warrants that he or she is duly authorized to execute and deliver this Lease on behalf of said corporation, limited liability company or other entity, as the case may be, and that this Lease is binding upon said entity in accordance with its terms without the joinder or approval of any other person.

40.      JOINT AND SEVERAL LIABILITY.  If Tenant is more than one natural person, the individuals collectively referred to herein as Tenant shall be jointly and severally liable with respect to the obligation to pay rent and all of the other obligations, covenants and agreements of Tenant set forth in this Lease.

41.      ADDENDA.  The provisions, if any, included at the end of this Lease, and any riders and exhibits appended to this Lease, are hereby made a part of this Lease as though set forth in full herein. Tenant acknowledges that Landlord is required to collect employment data from Tenants and shall cause Tenant to provide employment information in Exhibit F as of the Commencement Date and upon request by Landlord thereafter.  Tenant further agrees to complete the forms in Exhibits G & H and/or supply other reasonably available employment data from time to time as requested by Landlord.  Tenant agrees to complete such forms and provide such information in a timely manner upon request.

42.      OPTION TO EXPAND.  Provided that Tenant is not then in default beyond any applicable cure period under Section 24, Tenant shall have the right to expand the Premises by up to 7,853 square feet on the first floor, 103 E Badger Road (the “First Floor Expansion Space”), at the same terms and conditions under this Lease (except for Base Rent as provided below) commencing any time after 12/31/2013 with one hundred eighty (180) day prior notice.  If Tenant exercises its right to expand (gives notice) within the first eighteen (18) months of the Lease Term, Landlord shall provide a tenant improvement allowance of twenty-four and 77/100 dollars ($24.77) per square foot for the upfit of the First Floor Expansion Space and any additional upfit will be at Tenant’s expense. Base Rent for the First Floor Expansion Space shall be equal to $7.65 per rentable square foot escalated at two percent (2%) per annum with the escalation being calculated from the original Commencement Date of the Lease.

Tenant’s option to expand into the First Floor Expansion Space is subject to Landlord’s right to terminate as outlined in the existing Tenant’s current lease (AquaMost, Inc.) (the “AquaMost Lease”), which reads as follows: “Landlord reserves the right, provided the effective date of such termination is not before December 31, 2013, to relocate Tenant to substitute premises of comparable size within the Project Landlord shall provide Tenant with written notice by either: 1) 180 day notice, in which case Landlord will pay Tenant’s out of pocket costs incurred with moving its furniture and equipment, or 2) 120 day notice, in which case Landlord will pay Tenant $25,000 in addition to moving expenses described above (such additional fee shall not be paid if Landlord provides replacement property on terms acceptable to Tenant).  If Landlord does not offer a suitable substitute location or if Tenant does not agree on the substitute location within thirty (30) days after receipt of Landlord’s notice, this Lease shall terminate at the end of either the one hundred eighty (180) or one hundred twenty (120) day period following Landlord’s notice.

Should Tenant elect to expand into the First Floor Expansion Space and Landlord is obligated under the AquaMost Lease to pay the $25,000 and/or moving expense, Exact Sciences (Tenant) shall pay the actual, reasonable out of pocket expense to relocate AquaMost, Inc.  Notwithstanding the foregoing, Tenant recognizes Landlord’s desire to accommodate its other tenants in the building to the extent possible.  To that end, Tenant agrees to work in good faith with Landlord to minimize negative impacts to such other

17

tenants as a result of exercising its expansion rights.  This may include, to the extent practical, Tenant first exercising expansion rights in other areas of the building such as vacant space or the second floor space now occupied by Alexander Co.  Further, Tenant agrees in good faith to provide notice whether formal or informal as early as possible giving Landlord as much time as possible to accommodate its other tenants.

In addition, provided that Landlord has not leased (subject to Tenant’s right of first refusal) the space to a 3rd party other than the Alexander Company, Tenant shall have the right to expand into 5,810 square feet (145 E Badger Road, Suite 200) on the second floor (the “Second Floor Expansion Space”) “as is” by giving written notice to Landlord within the first eighteen (18) months of the Lease.  Base rent for the Second Floor Expansion Space shall be $13 / rsf NNN escalated at two percent (2%) per annum with the escalation being calculated from the original Commencement Date of the Lease.  Landlord shall provide new paint and carpet as part of this expansion into the Second Floor Expansion Space.  Tenant shall provide a one hundred twenty (120) day prior notice prior to the effective date of such expansion into the Second Floor Expansion Space.

If Tenant expands into either the First Floor Expansion Space or the Second Floor Expansion Space, Tenant shall extend the term of this Lease for a period of five (5) years from the effective date of the expansion, and such extension shall not be deemed an exercise of the Extension Option by Tenant.

In addition, Tenant shall have the right to expand into 3,189 square feet, if such room is not included in such square footage total, (145 E Badger Road, Suite 102) on the first floor (the “Suite 102 Expansion Space”) by giving written notice to Landlord within the first twelve (12) months of the Lease.  Base rent for the Suite 102 Expansion Space shall be $13 / rsf NNN escalated at two percent (2%) per annum with the escalation being calculated from the original Commencement Date of the Lease.  Landlord shall provide a tenant improvement allowance of four and 00/100 dollars ($4.00) per square foot per remaining lease year (including any pro-rata amount for any partial year remaining) for the upfit of the Suite 102 Expansion Space and any additional upfit will be at Tenant’s expense.  Tenant shall provide sixty (60) days prior notice of its desire to expand into the Suite 102 Expansion Space to allow Landlord to prepare such space for delivery to Tenant and such space shall be added to the Premises no later than one hundred eighty (180) days after such notice.  Tenant’s expansion into the Suite 102 Expansion Space shall be subject to Landlord’s ability to terminate the lease of any existing tenant in such space or relocate such tenant which Landlord shall use all reasonable efforts to do if Tenant exercises its right to expand into the Suite 102 Expansion Space.  Further, Tenant shall have the right to expand into the existing campus common conference room on the first floor of the building (the “Conference Room”) by giving written notice to Landlord within the first twelve (12) months of the Lease.  Base rent for the Conference Room shall be $13 / rsf NNN escalated at two percent (2%) per annum with the escalation being calculated from the original Commencement Date of the Lease.  Landlord shall provide a tenant improvement allowance of four and 00/100 dollars ($4.00) per square foot per remaining lease year (including any pro-rata amount for any partial year remaining) for the upfit of the Conference Room and any additional upfit will be at Tenant’s expense.  Tenant shall provide sixty (60) days prior notice of its desire to expand into the Conference Room to allow Landlord to prepare such space for delivery to Tenant and such space shall be added to the Premises no later than one hundred eighty (180) days after such notice.  Tenant’s expansion into the Conference Room shall be subject to Landlord’s ability to replace the Conference Room in another building in the Novation Campus at such time as suitable space becomes available at Landlord’s discretion.

If Tenant expands into the Suite 102 Expansion Space or the Conference Room, Tenant shall not be required to extend the term of this Lease unless expressly required to do so under the terms of the other expansion options described in this Section.

43.     RIGHT OF FIRST REFUSAL.  Provided that Tenant is not then in default beyond any applicable cure period under Section 24, Tenant will also have an ongoing Right of First Refusal on all remaining space within the Building (the “ROFR”).  If, during the term of the ROFR, Landlord receives a bona fide offer or letter of intent to lease any space within the Building (the “Additional Space”)(the “Offer”), and Landlord desires to accept the Offer, then Landlord shall deliver to Tenant written notice of Landlord’s intention to accept the Offer (the “Notice”), together with a copy of the Offer certified by Landlord to be a true and complete copy (such copy may have the identity of the offeror or omitted).  Tenant shall then have ten (10)

18

days, beginning with the date of delivery of the Notice, in which to notify Landlord in writing of Tenant’s election to amend this Lease to incorporate the Additional Space into this Lease on terms identical to those set forth in the Offer.  If Tenant exercises the ROFR by written notice given to Landlord within such ten (10)-day period, then Landlord and Tenant shall enter into an amendment to this Lease to incorporate into his Lease the Additional Space in accordance with the provisions of said Offer.  If, within ten (10) days of delivery by Landlord to Tenant of the Notice, Tenant has failed to exercise the ROFR pursuant to the terms of this Section, then the ROFR shall be null, void and of no further force and effect whatsoever as it applies to the Additional Space, provided that Landlord and the tenant that submitted the Offer enter into a binding lease in accordance with the Offer terms within 120 days after the date of the Notice.  The ROFR shall not apply to any options to extend that are currently contained in any existing leases.

44.      BROKERS. Landlord and Tenant represent and warrant each to the other that they have not dealt with any broker(s) or any other person claiming any entitlement to any commission in connection with this transaction except Broadwing Advisors (Craig Stanley) who represented Tenant and Alexander/RE (Andrew Schmidt) who represented Landlord (collectively, the “Brokers”).  Tenant agrees to indemnify and save Landlord harmless from and against any and all claims, suits, liabilities, costs, judgments and expenses, including reasonable attorneys’ fees, for any leasing commissions or other commissions, fees, charges or payments resulting from or arising out of its respective actions in connection with this Lease.  Landlord agrees to indemnify and save Tenant harmless from and against any and all claims, suits, liabilities, costs, judgments and expenses, including reasonable attorneys’ fees, for any leasing commissions or other commissions, fees, charges or payments resulting from or arising out of its actions in connection with this Lease.  Landlord agrees to be responsible for the leasing commission due the Brokers pursuant to a separate written agreement between Landlord and the Brokers, and to hold Tenant harmless respecting same.

19

EXECUTED as of the date first written above.

LANDLORD:				TENANT:
Tech Building I, LLC				Exact Sciences Laboratories, Inc.
By: Mid-Town Center, LLC, Manager
By:	/s/ Matthew D. Meier			By	/s/ Maneesh Arora
	Name: Matthew D. Meier				Name: Maneesh Arora
	Title: Manager				Title: CFO
	Date:		6/25/2013		Date:		6/25/2013
Attest:		/s/ Andrew Schmidt		Attest:		/s/ June Fontana
	Name:		Andrew Schmidt		Name:		June Fontana
	Title:		Principal Broker		Title:		Office Manager

20

EX-31.1

Exhibit 31.1

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Kevin T. Conroy, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Exact Sciences Corporation (the “registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 2, 2013	By:	/s/ Kevin T. Conroy
	Kevin T. Conroy
	President and Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Maneesh K. Arora, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Exact Sciences Corporation (the “registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 2, 2013	By:	/s/ Maneesh K. Arora
	Maneesh K. Arora
	Chief Operating Officer, Chief Financial Officer, and Secretary

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Exact Sciences Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kevin T. Conroy, President and Chief Executive Officer of the Company and Maneesh K. Arora, Chief Operating Officer, Chief Financial Officer and Secretary of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Kevin T. Conroy

Kevin T. Conroy

President and Chief Executive Officer

August 2, 2013

/s/ Maneesh K. Arora

Maneesh K. Arora
Chief Operating Officer, Chief Financial Officer, and Secretary

August 2, 2013

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers cash on hand, demand deposits in bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. The Company had no restricted cash at June 30, 2013 and December 31, 2012.

Marketable Securities

Marketable Securities

Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Marketable equity securities and debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the straight-line method, which approximates the effective interest method. Such amortization is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in investment income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

At June 30, 2013 and December 31, 2012, the Company’s investments were comprised of fixed income investments and all were deemed available-for-sale. The objectives of the Company’s investment strategy are to provide liquidity and safety of principal while striving to achieve the highest rate of return consistent with these two objectives.  The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. All of the Company’s investments are considered current. There were no realized losses for the six months ended June 30, 2013 and June 30, 2012.  Realized gains were $2,760 and $2,528 for the six months ended June 30, 2013 and 2012, respectively. Unrealized gains or losses on investments are recorded in other comprehensive loss.

Available-for-sale securities at June 30, 2013 consist of the following:

	June 30, 2013
(In thousands)	Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
U.S. government agency securities	$	49,156	$	40	$	—		$	49,196
Corporate bonds	73,771		—		(35		)	73,736
Certificates of deposit	8,272		12		—			8,284
Commercial paper	4,995		—		—			4,995
Total available-for-sale securities	$	136,194	$	52	$	(35	)	$	136,211

Available-for-sale securities at December 31, 2012 consist of the following:

	December 31, 2012
(In thousands)	Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income		Estimated Fair Value
U.S. government agency securities	$	44,270	$	38	$	—	$	44,308
Corporate bonds	43,303		27		—		43,330
Certificates of deposit	5,926		13		—		5,939
Commercial paper	1,199		—		—		1,199
Total available-for-sale securities	$	94,698	$	78	$	—	$	94,776

Net Loss Per Share

Net Loss Per Share

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period.  Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:

	June 30,
(In thousands)	2013	2012
Shares issuable upon exercise of stock options	6,249	6,320
Shares issuable upon exercise of outstanding warrants (1)	155	325
Shares issuable upon the release of restricted stock awards	875	884
Shares issuable upon the vesting of restricted stock awards related to a licensing agreement	49	73
	7,328	7,602

(1) At June 30, 2013, represents warrants to purchase 80,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.  At June 30, 2012, represents warrants to purchase 250,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.

Revenue Recognition

Revenue Recognition

License fees.   License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period. As more fully described in the 2012 Form 10-K, in connection with our January 2009 strategic transaction with Genzyme Corporation, Genzyme agreed to pay us a total of $18.5 million, of which $16.65 million was paid on January 27, 2009 and $1.85 million was subject to a holdback by Genzyme to satisfy certain potential indemnification obligations in exchange for the assignment and licensing of certain intellectual property to Genzyme. The Company’s on-going performance obligations to Genzyme under the Collaboration, License and Purchase Agreement (the “CLP Agreement”), as described below, including its obligation to deliver through licenses certain intellectual property improvements to Genzyme, if improvements are made during the initial five-year collaboration period, were deemed to be undelivered elements of the CLP Agreement on the date of closing. Accordingly, the Company deferred the initial $16.65 million in cash received at closing and is amortizing that up-front payment on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014. The Company received the first holdback amount of $962,000, which included accrued interest due, from Genzyme during the first quarter of 2010. The Company received the second holdback amount of $934,250, which included accrued interest due, from Genzyme during the third quarter of 2010.  The amounts were deferred and are being amortized on a straight-line basis into revenue over the remaining term of the collaboration at the time of receipt.

In addition, Genzyme purchased 3,000,000 shares of common stock on January 27, 2009 for $2.00 per share, representing a premium of $0.51 per share above the closing price of the Company’s common stock on that date of $1.49 per share. The aggregate premium paid by Genzyme over the closing price of the Company’s common stock on the date of the transaction of $1.53 million is deemed to be a part of the total consideration for the CLP Agreement. Accordingly, the Company deferred the aggregate $1.53 million premium and is amortizing that amount on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014.

The Company recognized approximately $1.0 million in license fee revenue in connection with the amortization of the up-front payments from Genzyme, during each of the three months ended June 30, 2013 and June 30, 2012. The Company recognized approximately $2.1 million in license fee revenue in connection with the amortization of up-front payments from Genzyme during each of the six months ended June 30, 2013 and June 30, 2012.

Reclassifications

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation in the financial statements and accompanying notes to the financial statements.

XML

Condensed Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Condensed Statements of Operations
License fees	$ 1,036	$ 1,036	$ 2,072	$ 2,072
Operating expenses:
Research and development	6,457	12,202	13,983	21,201
General and administrative	3,628	2,393	6,276	4,538
Sales and marketing	3,302	1,331	5,061	1,925
Total operating expenses	13,387	15,926	25,320	27,664
Loss from operations	(12,351)	(14,890)	(23,248)	(25,592)
Investment income	55	59	117	121
Interest expense	(18)	(5)	(37)	(10)
Net loss	$ (12,314)	$ (14,836)	$ (23,168)	$ (25,481)
Net loss per share-basic and diluted (in dollars per share)	$ (0.19)	$ (0.26)	$ (0.36)	$ (0.45)
Weighted average common shares outstanding-basic and diluted (in shares)	64,699	57,037	64,270	56,877

XML

MAYO LICENSE AGREEMENT

6 Months Ended

Jun. 30, 2013

MAYO LICENSE AGREEMENT

MAYO LICENSE AGREEMENT

(3) MAYO LICENSE AGREEMENT

Overview

On June 11, 2009, the Company entered into a license agreement (the “License Agreement”) with MAYO Foundation for Medical Education and Research (“MAYO”). Under the License Agreement, MAYO granted the Company an exclusive, worldwide license within the field (the “Field”) of stool or blood based cancer diagnostics and screening (excluding a specified proteomic target) with regard to certain MAYO patents, and a non-exclusive worldwide license within the Field with regard to certain MAYO know-how. The licensed patents cover advances in sample processing, analytical testing and data analysis associated with non-invasive, stool-based DNA screening for colorectal cancer. Under the License Agreement, the Company assumes the obligation and expense of prosecuting and maintaining the licensed patents and is obligated to make commercially reasonable efforts to bring products covered by the license to market. Pursuant to the License Agreement, the Company granted MAYO two common stock purchase warrants with an exercise price of $1.90 per share covering 1,000,000 and 250,000 shares of common stock, respectively. The Company is also required to make payments to MAYO for up-front fees, fees once certain milestones are reached by the Company, and other payments as outlined in the License Agreement. In addition to the license to intellectual property owned by MAYO, the Company receives product development and research and development efforts from MAYO personnel. The Company determined that the payments made for intellectual property should not be capitalized as the future economic benefit derived from the transactions is uncertain. The Company is also obligated to make royalty payments to MAYO on potential future net sales of any products developed from the licensed technology.

Warrants

The warrants granted to MAYO were valued based on a Black-Scholes pricing model at the date of the grant. The warrants were granted with an exercise price of $1.90 per share of common stock. The grant to purchase 1,000,000 shares was immediately exercisable and the grant to purchase 250,000 shares vests and becomes exercisable over a four year period.

In March of 2010, MAYO partially exercised its warrant covering 1,000,000 shares by utilizing the cashless exercise provision contained in the warrant.  As a result of this exercise for a gross amount of 200,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 86,596 shares leaving it with a net amount of 113,404 shares.

In September of 2010, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant.  As a result of this exercise for a gross amount of 300,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 97,853 shares leaving it with a net amount of 202,147 shares.

In June of 2011, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 250,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 60,246 shares leaving it with a net amount of 189,754 shares.

In September of 2011, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 250,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 56,641 shares leaving it with a net amount of 193,359 shares. Following this exercise, the warrant covering 1,000,000 shares was fully exercised.

In January of 2013, MAYO partially exercised its warrant covering 250,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 85,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 14,008 shares leaving it with a net amount of 70,992 shares.

In June of 2013, MAYO partially exercised its warrant covering a remaining 165,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 85,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 12,765 shares leaving it with a net amount of 72,235 shares. The warrant now covers a total of 80,000 shares.

Royalty Payments

The Company will make royalty payments to MAYO based on a percentage of net sales of products developed from the licensed technology starting in the third year of the agreement.  Minimum royalty payments were $10,000 in 2012 and will be $25,000 per year through 2029, the year the last patent expires.

Other Payments

Other payments under the MAYO agreement include an upfront payment of $80,000, a milestone payment of $250,000 on the commencement of patient enrollment in FDA trials for the Company’s Cologuard pre-cancer and cancer screening test, and a $500,000 payment upon FDA approval of the Company’s Cologuard test.  The upfront payment of $80,000 was made in the third quarter of 2009 and expensed to research and development in the second quarter of 2009. The Company began enrollment in its FDA trial in June of 2011 and the milestone payment of $250,000 was made in June of 2011 and expensed to research and development in the second quarter of 2011.  It is uncertain as to when the FDA will approve the Company’s pre-cancer and cancer screening test. Therefore, the $500,000 milestone payment has not been recorded as a liability. The Company evaluates the status of the FDA trial at each reporting date to determine if a liability should be recorded for the milestone payment.

In addition, the Company is making payments to MAYO for research and development efforts.  During the three and six months ended June 30, 2013, the Company made payments of $0.3 million and $0.5 million, respectively. At June 30, 2013 the Company recorded an estimated liability in the amount of $0.5 million for research and development efforts.  During the three and six months ended June 30, 2012, the Company made payments of $0.2 million. At June 30, 2012 the Company recorded an estimated liability in the amount of $0.2 million for research and development efforts.

May 2012 Amendment

In May 2012 the Company expanded the relationship with MAYO through an amendment to the License Agreement. As part of the amendment, MAYO expanded the Company’s license to include all gastrointestinal cancers and diseases, and new cancer screening applications of stool- and blood-based testing. As consideration for the expanded license, the Company granted MAYO 97,466 shares of restricted stock, one quarter of which vested immediately, with the remainder to vest in three equal annual installments. The Company recognized $1.0 million in licensing expense during the twelve months ended December 31, 2012 in connection with the restricted stock grant due to the uncertainty in the license providing a future benefit.

As part of the amendment, the Company will also be responsible for making additional restricted stock grants to MAYO as certain milestones are met with respect to commercial launch of the Company’s second and third licensed products. Additionally, the Company will make milestone payments once certain sales levels are reached on the second and third licensed products. It is uncertain as to when these milestones will be met; therefore, the milestone payments have not been recorded as a liability. The Company evaluates the status of the milestone payments at each reporting date to determine if a liability should be recorded for the milestone payment.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) (USD $)	3 Months Ended		6 Months Ended				0 Months Ended	1 Months Ended	3 Months Ended				6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 21, 2013	Dec. 31, 2012	Jan. 27, 2009 CLP Agreement Genzyme Corporation	Jan. 31, 2009 CLP Agreement Genzyme Corporation	Jun. 30, 2013 CLP Agreement Genzyme Corporation	Jun. 30, 2012 CLP Agreement Genzyme Corporation	Sep. 30, 2010 CLP Agreement Genzyme Corporation	Mar. 31, 2010 CLP Agreement Genzyme Corporation	Jun. 30, 2013 CLP Agreement Genzyme Corporation	Jun. 30, 2012 CLP Agreement Genzyme Corporation
License fees
Amount received							$ 16,650,000				$ 934,250	$ 962,000
Amount of Deferred Revenue							16,650,000
Total agreed consideration amount								18,500,000
Amount subject to holdback								1,850,000
Initial collaboration period								5 years
Sale of common stock (in shares)	70,662,697		70,662,697			63,909,800	3,000,000
Price at which share of common stock are sold (in dollars per share)							$ 2.00
Premium above closing price of common stock at which shares are sold (in dollars per share)							$ 0.51
Closing price of common stock (in dollars per share)					$ 12.35		$ 1.49
Aggregate premium received over the closing price of common stock							1,530,000
Amount of premium being amortized							1,530,000
License fee revenue	$ 1,036,000	$ 1,036,000	$ 2,072,000	$ 2,072,000					$ 1,000,000	$ 1,000,000			$ 2,100,000	$ 2,100,000

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of available-for-sale securities

	June 30, 2013
(In thousands)	Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
U.S. government agency securities	$	49,156	$	40	$	—		$	49,196
Corporate bonds	73,771		—		(35		)	73,736
Certificates of deposit	8,272		12		—			8,284
Commercial paper	4,995		—		—			4,995
Total available-for-sale securities	$	136,194	$	52	$	(35	)	$	136,211

	December 31, 2012
(In thousands)	Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income		Estimated Fair Value
U.S. government agency securities	$	44,270	$	38	$	—	$	44,308
Corporate bonds	43,303		27		—		43,330
Certificates of deposit	5,926		13		—		5,939
Commercial paper	1,199		—		—		1,199
Total available-for-sale securities	$	94,698	$	78	$	—	$	94,776

Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect

	June 30,
(In thousands)	2013	2012
Shares issuable upon exercise of stock options	6,249	6,320
Shares issuable upon exercise of outstanding warrants (1)	155	325
Shares issuable upon the release of restricted stock awards	875	884
Shares issuable upon the vesting of restricted stock awards related to a licensing agreement	49	73
	7,328	7,602

(1) At June 30, 2013, represents warrants to purchase 80,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.  At June 30, 2012, represents warrants to purchase 250,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.

XML

STOCK-BASED COMPENSATION (Details 2) (Restricted stock units)	6 Months Ended
	Jun. 30, 2013 item	Jun. 30, 2013 Chief Commercial Officer	Jun. 07, 2013 Chief Commercial Officer
Shares reserved for issuance
Number of shares affected by modification of options held by Ms. Laura Stoltenberg		41,250	100,000
Number of shares that will vest	48,750	10,000
Number of installments for vesting of shares	24

XML

STOCK-BASED COMPENSATION (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
STOCK-BASED COMPENSATION
Stock-based compensation	$ 2,800	$ 1,500	$ 3,811	$ 2,459

XML

OPERATING LEASE (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013 sqft item
OPERATING LEASE
Lease term	5 years
Area of laboratory office facility under operating lease (in square feet)	29,000
Number of extensions of lease term	2
Future minimum payments under operating leases
2013	$ 112
2014	676
2015	680
2016	684
2017	689
2018	578
Total lease obligations	$ 3,419

XML

MAYO LICENSE AGREEMENT (Details) (USD $)	0 Months Ended	1 Months Ended			1 Months Ended			3 Months Ended			6 Months Ended		12 Months Ended	1 Months Ended					0 Months Ended	1 Months Ended		6 Months Ended
	Jun. 21, 2013	May 31, 2012 item	Jun. 30, 2013	Dec. 31, 2009	May 31, 2012 License Agreement MAYO	Jun. 30, 2011 License Agreement MAYO	Jun. 30, 2009 License Agreement MAYO item	Jun. 30, 2013 License Agreement MAYO	Jun. 30, 2012 License Agreement MAYO	Sep. 30, 2009 License Agreement MAYO	Jun. 30, 2013 License Agreement MAYO	Jun. 30, 2012 License Agreement MAYO	Dec. 31, 2012 License Agreement MAYO	Sep. 30, 2011 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Jun. 30, 2011 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Sep. 30, 2010 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Mar. 31, 2010 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Jun. 11, 2009 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Jun. 11, 2009 License Agreement MAYO Warrant covering 250,000 shares of common stock	Jun. 30, 2013 License Agreement MAYO Warrant covering 250,000 shares of common stock	Jan. 31, 2013 License Agreement MAYO Warrant covering 250,000 shares of common stock	Jun. 30, 2013 License Agreement MAYO Warrant covering 250,000 shares of common stock
Warrants
Number of common stock purchase warrants granted							2
Exercise price (in dollars per share)			$ 0.01															$ 1.90	$ 1.90
Number of shares of common stock covered by warrants				75,000														1,000,000	250,000	80,000		80,000
Vesting period of warrant (in years)																			4 years			4 years
Warrants exercised, gross (in shares)														250,000	250,000	300,000	200,000			85,000	85,000
Warrants forfeited (in shares)														56,641	60,246	97,853	86,596			12,765	14,008
Warrants exercised, net of forfeiture (in shares)														193,359	189,754	202,147	113,404			72,235	70,992	165,000
Royalty Payments
Minimum royalty payments								$ 25,000			$ 25,000		$ 10,000
Other Payments
Upfront payment										80,000
Milestone payment on the commencement of patient enrollment in a human cancer screening clinical											250,000
Milestone payment contingent upon FDA approval						250,000					500,000
Payments for research and development efforts								300,000	200,000		500,000	200,000
Estimated liability for research and development efforts								500,000	200,000		500,000	200,000
Amendments - May 2012
Number of shares of restricted stock granted as a consideration for the expanded license	6,325,000				97,466
Vesting right percentage of restricted stock		25.00%
Number of equal annual installments in which restricted stock are to be vested		3
Licensing expense recognized in connection with the restricted stock grant													$ 1,000,000

XML

Condensed Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (23,168)	$ (25,481)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	646	417
Loss on disposal of property and equipment	91
Stock-based compensation	3,811	2,459
Amortization of deferred license fees	(2,072)	(2,072)
Warrant licensing expense		152
Restricted stock licensing expense		1,000
Amortization of premium on short-term investments	270	220
Changes in assets and liabilities:
Prepaid expenses and other current assets	(494)	(1,313)
Accounts payable	(2,568)	2
Accrued expenses	1,515	1,128
Accrued interest	10	10
Net cash used in operating activities	(21,959)	(23,478)
Cash flows from investing activities:
Purchases of marketable securities	(71,833)	(33,764)
Maturities of marketable securities	30,067	26,352
Purchases of property and equipment	(1,726)	(729)
Net cash used in investing activities	(43,492)	(8,141)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	73,302
Proceeds from exercise of common stock options and stock purchase plan	486	1,864
Payments on capital lease obligations	(164)
Net cash provided by financing activities	73,624	1,864
Net increase (decrease) in cash and cash equivalents	8,173	(29,755)
Cash and cash equivalents, beginning of period	13,345	35,781
Cash and cash equivalents, end of period	21,518	6,026
Supplemental disclosure of non-cash investing and financing activities:
Unrealized gain (loss) on available-for-sale investments	7	67
Issuance of 30,534 and 32,872 shares of common stock to fund the Company's 401(k) matching contribution for 2012 and 2011, respectively	354	274
Conversion of accrued expenses into 34,442 and 34,336 shares of common stock in connection with the Company's Employee Stock Purchase Plan for 2013 and 2012, respectively.	$ 261	$ 194

XML

ORGANIZATION AND BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2013

ORGANIZATION AND BASIS OF PRESENTATION

ORGANIZATION AND BASIS OF PRESENTATION

(1) ORGANIZATION AND BASIS OF PRESENTATION

Organization

Exact Sciences Corporation (“Exact,” “we,” “us” or the “Company”) was incorporated in February 1995. Exact is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. The Company’s non-invasive stool-based DNA (sDNA) screening technology includes proprietary and patented methods that isolate and analyze human DNA present in stool to screen for the presence of colorectal pre-cancer and cancer.

Basis of Presentation

The accompanying condensed financial statements of the Company are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K (the “2012 Form 10-K”). These condensed financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair presentation of the results of operations have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2012 Form 10-K.  Management has evaluated subsequent events for disclosure or recognition in the accompanying financial statements up to the filing of this report.

XML

STOCK-BASED COMPENSATION

6 Months Ended

Jun. 30, 2013

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

(4) STOCK-BASED COMPENSATION

Stock-Based Compensation Plans

The Company maintains the 2010 Omnibus Long-Term Incentive Plan, the 2010 Employee Stock Purchase Plan,  the 2000 Stock Option and Incentive Plan and the 2000 Employee Stock Purchase Plan (collectively, the “Stock Plans”).

Stock-Based Compensation Expense

The Company recorded $2.8 million and $3.8 million in stock-based compensation expense during the three and six months ended June 30, 2013 in connection with the amortization of restricted stock and restricted stock unit awards, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors.   The Company recorded $1.5 million and $2.5 million in stock-based compensation expense during the three and six months ended June 30, 2012 in connection with the amortization of restricted stock and restricted stock unit awards, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees and non-employee directors.

In connection with the June 7, 2013 resignation of Laura Stoltenberg, the Company’s former Chief Commercial Officer, the Company modified the vesting of 100,000 shares of Ms. Stoltenberg’s previously unvested restricted stock units of which 41,250 of the restricted stock units vested upon the execution of the separation agreement, 10,000 will vest in March 2014, and the remaining 48,750 will vest in twenty-four equal monthly installments beginning in April 2014, subject to Ms. Stoltenberg’s continuing compliance with the terms of the separation agreement.  Ms. Stoltenberg forfeited all other unvested restricted stock units and stock option awards. It was determined that the continuing compliance and service to be provided to the Company under the separation agreement was not substantive and, as a result, the Company recorded the full value of the modified restricted stock units as additional stock-based compensation expense in the second quarter of 2013.

Determining Fair Value

Valuation and Recognition - The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model based on the assumptions in the table below. The estimated fair value of employee stock options is recognized to expense using the straight-line method over the vesting period.

Expected Term - The Company uses the simplified calculation of expected life, described in the SEC’s Staff Accounting Bulletins 107 and 110, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected life.  Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.

Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.

Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest.  A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates.  The Company’s forfeiture rate used in the six months ended June 30, 2013 was 2.76%. The Company’s forfeiture rate used in the six months ended June 30, 2012 was 1.38%.

The fair value of each restricted stock and restricted stock unit award is determined on the date of grant using the closing stock price on that day.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Option Plan Shares
Risk-free interest rates	0.94%		0.82%		0.94% - 1.15%		0.82% - 0.84%
Expected term (in years)	6		6		6		6
Expected volatility	82.9%		87.1%		82.9% - 84.0%		87.1% - 91.6%
Dividend yield	0%		0%		0%		0%
Weighted average fair value per share of options granted during the period	$	6.55	$	7.38	$	7.66	$	6.86
ESPP Shares
Risk-free interest rates	0.11% - 0.20%		0.19% - 0.27%		0.11% - 0.20%		0.19% - 0.27%
Expected term (in years)	0.5-2		0.5 - 2		0.5-2		0.5 - 2
Expected volatility	39.1% - 45.6%		39.6% - 54.9%		39.1% - 45.6%		39.6% - 54.9%
Dividend yield	0%		0%		0%		0%
Weighted average fair value per share of stock purchase rights granted during the period	$	2.80	$	3.47	$	2.80	$	3.47

Stock Option and Restricted Stock Activity

A summary of stock option activity under the Stock Plans during the six months ended June 30, 2013 is as follows:

					Weighted
			Weighted		Average
			Average		Remaining	Aggregate
			Exercise		Contractual	Intrinsic
Options	Shares		Price		Term (Years)	Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 2013	6,181,996		$	2.62	6.6	$	49,439
Granted	240,570		$	10.72
Exercised	(98,869	)	$	4.99
Forfeited	(74,250	)	$	8.67
Outstanding, June 30, 2013	6,249,447		$	2.83	6.2	$	69,266
Exercisable, June 30, 2013	5,205,858		$	1.84	5.8	$	62,849
Vested and expected to vest June 30, 2013	6,220,586		$	2.84	6.2	$	69,089

(1)The aggregate intrinsic value of options outstanding, exercisable and vested and expected to vest is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s common stock for options that had exercise prices that were lower than the $13.91 market price of the Company’s common stock at June 30, 2013.  The total intrinsic value of options exercised during the six months ended June 30, 2013 was $0.5 million. The total intrinsic value of options exercised during the six months ended June 30, 2012 was $3.4 million.

As of June 30, 2013, there was $11.0 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under all Stock Plans.  Total unrecognized compensation cost will be adjusted for future changes in forfeitures.  The Company expects to recognize that cost over a weighted average period of 2.85 years.

A summary of restricted stock activity under the Stock Plans during the six months ended June 30, 2013 is as follows:

			Weighted
	Restricted		Average Grant
	Shares		Date Fair Value
Outstanding, January 1, 2013	813,955		$	8.51
Granted	581,124		$	10.77
Released	(166,843	)	$	8.63
Forfeited	(352,836	)	$	9.45
Outstanding, June 30, 2013	875,400		$	9.61

During the first quarter of 2012, the Company granted a total of 262,500 restricted stock units to certain executives that would have vested based upon the satisfaction of certain service and performance conditions. These performance conditions were not met and the awards were forfeited during the first quarter of 2013. The expense recorded through December 31, 2012 for these awards totaling $0.6 million was reversed during the first quarter of 2013 due to the forfeiture.

During the first quarter of 2013, the Company granted a total of 180,750 restricted stock units to certain executives that will vest based upon the satisfaction of certain service and performance conditions.  The Company performed an evaluation of internal and external factors, and determined the number of shares that are most likely to vest based on the probability of which performance conditions will be met. The expense for the fair value of the awards that are expected to vest is being recognized ratably over the vesting period.

Warrants to purchase 75,000 shares of common stock were issued in connection with a consulting agreement in 2009. The warrants contain a performance condition and vest if the Company successfully receives FDA approval for its Cologuard test. The Company is uncertain if the performance conditions will be attained, and therefore no expense has been recorded on this warrant as of June 30, 2013. The exercise price of the warrant is $0.01.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers cash on hand, demand deposits in bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. The Company had no restricted cash at June 30, 2013 and December 31, 2012.

Marketable Securities

Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Marketable equity securities and debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the straight-line method, which approximates the effective interest method. Such amortization is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in investment income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

At June 30, 2013 and December 31, 2012, the Company’s investments were comprised of fixed income investments and all were deemed available-for-sale. The objectives of the Company’s investment strategy are to provide liquidity and safety of principal while striving to achieve the highest rate of return consistent with these two objectives.  The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. All of the Company’s investments are considered current. There were no realized losses for the six months ended June 30, 2013 and June 30, 2012.  Realized gains were $2,760 and $2,528 for the six months ended June 30, 2013 and 2012, respectively. Unrealized gains or losses on investments are recorded in other comprehensive loss.

Available-for-sale securities at June 30, 2013 consist of the following:

	June 30, 2013
(In thousands)	Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
U.S. government agency securities	$	49,156	$	40	$	—		$	49,196
Corporate bonds	73,771		—		(35		)	73,736
Certificates of deposit	8,272		12		—			8,284
Commercial paper	4,995		—		—			4,995
Total available-for-sale securities	$	136,194	$	52	$	(35	)	$	136,211

Available-for-sale securities at December 31, 2012 consist of the following:

	December 31, 2012
(In thousands)	Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income		Estimated Fair Value
U.S. government agency securities	$	44,270	$	38	$	—	$	44,308
Corporate bonds	43,303		27		—		43,330
Certificates of deposit	5,926		13		—		5,939
Commercial paper	1,199		—		—		1,199
Total available-for-sale securities	$	94,698	$	78	$	—	$	94,776

Net Loss Per Share

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period.  Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:

	June 30,
(In thousands)	2013	2012
Shares issuable upon exercise of stock options	6,249	6,320
Shares issuable upon exercise of outstanding warrants (1)	155	325
Shares issuable upon the release of restricted stock awards	875	884
Shares issuable upon the vesting of restricted stock awards related to a licensing agreement	49	73
	7,328	7,602

(1) At June 30, 2013, represents warrants to purchase 80,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.  At June 30, 2012, represents warrants to purchase 250,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.

Revenue Recognition

License fees.   License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period. As more fully described in the 2012 Form 10-K, in connection with our January 2009 strategic transaction with Genzyme Corporation, Genzyme agreed to pay us a total of $18.5 million, of which $16.65 million was paid on January 27, 2009 and $1.85 million was subject to a holdback by Genzyme to satisfy certain potential indemnification obligations in exchange for the assignment and licensing of certain intellectual property to Genzyme. The Company’s on-going performance obligations to Genzyme under the Collaboration, License and Purchase Agreement (the “CLP Agreement”), as described below, including its obligation to deliver through licenses certain intellectual property improvements to Genzyme, if improvements are made during the initial five-year collaboration period, were deemed to be undelivered elements of the CLP Agreement on the date of closing. Accordingly, the Company deferred the initial $16.65 million in cash received at closing and is amortizing that up-front payment on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014. The Company received the first holdback amount of $962,000, which included accrued interest due, from Genzyme during the first quarter of 2010. The Company received the second holdback amount of $934,250, which included accrued interest due, from Genzyme during the third quarter of 2010.  The amounts were deferred and are being amortized on a straight-line basis into revenue over the remaining term of the collaboration at the time of receipt.

In addition, Genzyme purchased 3,000,000 shares of common stock on January 27, 2009 for $2.00 per share, representing a premium of $0.51 per share above the closing price of the Company’s common stock on that date of $1.49 per share. The aggregate premium paid by Genzyme over the closing price of the Company’s common stock on the date of the transaction of $1.53 million is deemed to be a part of the total consideration for the CLP Agreement. Accordingly, the Company deferred the aggregate $1.53 million premium and is amortizing that amount on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014.

The Company recognized approximately $1.0 million in license fee revenue in connection with the amortization of the up-front payments from Genzyme, during each of the three months ended June 30, 2013 and June 30, 2012. The Company recognized approximately $2.1 million in license fee revenue in connection with the amortization of up-front payments from Genzyme during each of the six months ended June 30, 2013 and June 30, 2012.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation in the financial statements and accompanying notes to the financial statements.

XML

STOCK-BASED COMPENSATION (Details 3) (USD $)	3 Months Ended		6 Months Ended				3 Months Ended		6 Months Ended		12 Months Ended	6 Months Ended				3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended			12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 21, 2013	Dec. 31, 2009	Jun. 30, 2013 Option Plan Shares	Jun. 30, 2012 Option Plan Shares	Jun. 30, 2013 Option Plan Shares	Jun. 30, 2012 Option Plan Shares	Dec. 31, 2012 Option Plan Shares	Jun. 30, 2013 Option Plan Shares Maximum	Jun. 30, 2012 Option Plan Shares Maximum	Jun. 30, 2013 Option Plan Shares Minimum	Jun. 30, 2012 Option Plan Shares Minimum	Jun. 30, 2013 ESPP Shares	Jun. 30, 2012 ESPP Shares	Jun. 30, 2013 ESPP Shares	Jun. 30, 2012 ESPP Shares	Jun. 30, 2013 ESPP Shares Maximum	Jun. 30, 2012 ESPP Shares Maximum	Jun. 30, 2013 ESPP Shares Maximum	Jun. 30, 2012 ESPP Shares Maximum	Jun. 30, 2013 ESPP Shares Minimum	Jun. 30, 2012 ESPP Shares Minimum	Jun. 30, 2013 ESPP Shares Minimum	Jun. 30, 2012 ESPP Shares Minimum	Jun. 30, 2013 Restricted stock and restricted stock unit	Mar. 31, 2013 Restricted stock and restricted stock unit	Mar. 31, 2012 Restricted stock and restricted stock unit	Dec. 31, 2012 Restricted stock and restricted stock unit
STOCK-BASED COMPENSATION
Forfeiture rate (as a percent)			2.76%	1.38%
Valuation assumptions
Risk-free interest rates (as a percent)							0.94%	0.82%
Risk-free interest rates, minimum (as a percent)														0.94%	0.82%									0.11%	0.19%	0.11%	0.19%
Risk-free interest rates, maximum (as a percent)												1.15%	0.84%							0.20%	0.27%	0.20%	0.27%
Expected term							6 years	6 years	6 years	6 years										2 years	2 years	2 years	2 years	6 months	6 months	6 months	6 months
Expected volatility (as a percent)							82.90%	87.10%
Expected volatility, minimum (as a percent)														82.90%	87.10%									39.10%	39.60%	39.10%	39.60%
Expected volatility, maximum (as a percent)												84.00%	91.60%							45.60%	54.90%	45.60%	54.90%
Dividend yield (as a percent)							0.00%	0.00%	0.00%	0.00%						0.00%	0.00%	0.00%	0.00%
Weighted average fair value per share of options granted during the period (in dollars per share)							$ 6.55	$ 7.38	$ 7.66	$ 6.86						$ 2.80	$ 3.47	$ 2.80	$ 3.47
Shares
Outstanding at the beginning of the period (in shares)									6,181,996
Granted (in shares)							240,570																						180,750	262,500
Exercised (in shares)							(98,869)
Forfeited (in shares)							(74,250)
Outstanding at the end of the period (in shares)							6,249,447		6,249,447		6,181,996
Exercisable at the end of the period (in shares)							5,205,858		5,205,858
Vested and expected to vest at the end of the period (in shares)							6,220,586		6,220,586
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)									$ 2.62
Granted (in dollars per share)							$ 10.72
Exercised (in dollars per share)							$ 4.99
Forfeited (in dollars per share)							$ 8.67
Outstanding at the end of the period (in dollars per share)							$ 2.83		$ 2.83		$ 2.62
Exercisable at the end of the period (in dollars per share)							$ 1.84		$ 1.84
Vested and expected to vest at the end of the period (in dollars per share)							$ 2.84		$ 2.84
Weighted Average Remaining Contractual Term
Outstanding at the end of the period							6 years 2 months 12 days				6 years 7 months 6 days
Exercisable at the end of the period							5 years 9 months 18 days
Vested and expected to vest at the end of the period							6 years 2 months 12 days
Aggregate Intrinsic Value
Outstanding at the end of the period							$ 69,266,000		$ 69,266,000		$ 49,439,000
Exercisable at the end of the period							62,849,000		62,849,000
Vested and expected to vest at the end of the period							69,089,000		69,089,000
Additional disclosures
Market price (in dollars per share)					$ 12.35		$ 13.91		$ 13.91
Total intrinsic value of options exercised									500,000	3,400,000
Restricted Shares
Outstanding at the beginning of the period (in shares)																													813,955
Granted (in shares)																												581,124
Released (in shares)																												(166,843)
Forfeited (in shares)																												(352,836)
Outstanding at the end of the period (in shares)																												875,400			813,955
Unrecognized compensation cost	11,000,000		11,000,000
Weighted average period for recognition of unrecognized compensation cost			2 years 10 months 6 days
Weighted Average Grant Date Fair Value
Outstanding at the beginning of the period (in dollars per share)																													$ 8.51
Granted (in dollars per share)																												$ 10.77
Released (in dollars per share)																												$ 8.63
Forfeited (in dollars per share)																												$ 9.45
Outstanding at the end of the period (in dollars per share)																												$ 9.61			$ 8.51
Stock-based compensation	2,800,000	1,500,000	3,811,000	2,459,000																									(600,000)		600,000
Number of shares of common stock covered by warrants issued in connection with a consulting agreement						75,000
Expense related to stock warrants			$ 0
Exercise price (in dollars per share)	$ 0.01		$ 0.01

XML

RELATED PARTY TRANSACTIONS (Details) (Non-employee director, USD $)	3 Months Ended
	Sep. 30, 2012
RELATED PARTY TRANSACTIONS
Consulting agreement term	1 year
Restricted stock award
RELATED PARTY TRANSACTIONS
Shares of common stock granted	4,873
Vesting period of awards granted	1 year
Cash payable over term of agreement	$ 60,000

XML

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Condensed Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, Authorized shares	5,000,000	5,000,000
Preferred stock, Issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, Authorized shares	100,000,000	100,000,000
Common stock, Issued shares	70,662,697	63,909,800
Common stock, outstanding shares	70,662,697	63,909,800

XML

OPERATING LEASE

6 Months Ended

Jun. 30, 2013

OPERATING LEASE

OPERATING LEASE

(7) OPERATING LEASE

During the second quarter of 2013, the Company entered into a five year lease for a 29,000 square foot facility in Madison, Wisconsin to house our commercial lab operations. This lease contains periodic rent escalation adjustments and includes provisions for tenant improvements. The Company has two, five year options to extend the term of the lease.

Future minimum payments under the operating lease are as follows as of June 30, 2013. Amounts included in the table are in thousands.

Year Ending December 31,
2013	$	112
2014	676
2015	680
2016	684
2017	689
2018	578
Total lease obligations	$	3,419

XML

Condensed Statements of Comprehensive Loss (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Condensed Statements of Comprehensive Loss
Net loss	$ (12,314)	$ (14,836)	$ (23,168)	$ (25,481)
Other comprehensive loss, net of tax
Unrealized holding gain (loss) on available-for-sale investments	(54)	32	(61)	67
Comprehensive loss	$ (12,368)	$ (14,804)	$ (23,229)	$ (25,414)

XML

Condensed Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 21,518	$ 13,345
Marketable securities	136,211	94,776
Prepaid expenses and other current assets	1,087	593
Total current assets	158,816	108,714
Property and Equipment, at cost:
Laboratory equipment	5,042	4,051
Office and computer equipment	1,396	824
Leasehold improvements	283	283
Furniture and fixtures	28	28
Property and Equipment, gross	6,749	5,186
Less-Accumulated depreciation	(2,355)	(1,781)
Property and Equipment, net	4,394	3,405
TOTAL ASSETS	163,210	112,119
Current Liabilities:
Accounts payable	1,084	3,652
Accrued expenses	4,227	3,327
Capital lease obligation, current portion	342	333
Deferred license fees, current portion	2,366	4,143
Total current liabilities	8,019	11,455
Long-term debt	1,000	1,000
Long-term accrued interest	73	63
Capital lease obligation, less current portion	538	711
Deferred license fees, less current portion		295
Commitments and contingencies
Stockholders' Equity:
Preferred stock, $0.01 par value Authorized-5,000,000 shares Issued and outstanding-no shares at June 30, 2013 and December 31, 2012
Common stock, $0.01 par value Authorized-100,000,000 shares Issued and outstanding-70,662,697 and 63,909,800 shares at June 30, 2013 and December 31, 2012	707	639
Additional paid-in capital	450,269	372,123
Other comprehensive income	17	78
Accumulated deficit	(297,413)	(274,245)
Total stockholders' equity	153,580	98,595
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 163,210	$ 112,119

XML

FAIR VALUE MEASUREMENTS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Marketable securities
Available-for-sale securities	$ 136,211,000	$ 94,776,000
Available-for-sale securities in a continuous unrealized loss position
Total unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months	58,184	4,800
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Due in one year or less	71,940,000
Due after one year through two years	64,271,000
Estimated Fair Value	136,211,000	94,776,000
Contractual maturities of the available-for-sale investments in debt securities, Cost
Due in one year or less	71,915,000
Due after one year through two years	64,279,000
Cost	136,194,000
Total unrealized losses of available for sale securities in a continuous unrealized loss position for greater than twelve months	0	0
Fair Value
Marketable securities
Available-for-sale securities	157,729,000	108,121,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	157,729,000	108,121,000
Fair Value | Cash equivalents
Marketable securities
Cash and money market	12,567,000	13,095,000
Certificates of deposit	8,951,000
Fair Value | U.S. government agency securities
Marketable securities
Available-for-sale securities	49,196,000	44,308,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	49,196,000	44,308,000
Fair Value | Corporate bonds
Marketable securities
Corporate bond		250,000
Available-for-sale securities	73,736,000	43,330,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	73,736,000	43,330,000
Fair Value | Certificates of deposit
Marketable securities
Available-for-sale securities	8,284,000	5,939,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	8,284,000	5,939,000
Fair Value | Commercial paper
Marketable securities
Available-for-sale securities	4,995,000	1,199,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	4,995,000	1,199,000
Quoted Prices in Active Markets for Identical Assets (Level1)
Marketable securities
Cash and money market	12,567,000	13,095,000
Quoted Prices in Active Markets for Identical Assets (Level1) | Cash equivalents
Marketable securities
Cash and money market	12,567,000	13,095,000
Significant Other Observable Inputs (Level 2)
Marketable securities
Long-term debt	1,000,000	1,000,000
Available-for-sale securities	145,162,000	95,026,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	145,162,000	95,026,000
Significant Other Observable Inputs (Level 2) | Cash equivalents
Marketable securities
Certificates of deposit	8,951,000
Significant Other Observable Inputs (Level 2) | U.S. government agency securities
Marketable securities
Available-for-sale securities	49,196,000	44,308,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	49,196,000	44,308,000
Significant Other Observable Inputs (Level 2) | Corporate bonds
Marketable securities
Corporate bond		250,000
Available-for-sale securities	73,736,000	43,330,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	73,736,000	43,330,000
Significant Other Observable Inputs (Level 2) | Certificates of deposit
Marketable securities
Available-for-sale securities	8,284,000	5,939,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	8,284,000	5,939,000
Significant Other Observable Inputs (Level 2) | Commercial paper
Marketable securities
Available-for-sale securities	4,995,000	1,199,000
Contractual maturities of the available-for-sale investments in debt securities, Fair Value
Estimated Fair Value	$ 4,995,000	$ 1,199,000

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Common shares not included in the computation of diluted net loss per share
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect	7,328,000	7,602,000
Additional disclosure
Number of shares of common stock that can be purchased through issuance of warrants under a license agreement	80,000	250,000
Number of shares of common stock that can be purchased through issuance of warrants under a consulting agreement	75,000	75,000
Shares issuable upon exercise of stock options
Common shares not included in the computation of diluted net loss per share
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect	6,249,000	6,320,000
Shares issuable upon exercise of outstanding warrants
Common shares not included in the computation of diluted net loss per share
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect	155,000	325,000
Shares of restricted stock awards outstanding
Common shares not included in the computation of diluted net loss per share
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect	875,000	884,000
Shares issuable upon the vesting of restricted stock awards related to licensing agreement
Common shares not included in the computation of diluted net loss per share
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect	49,000	73,000

XML

EQUITY

6 Months Ended

Jun. 30, 2013

EQUITY

EQUITY

(6) EQUITY

On June 21, 2013, the Company completed an underwritten public offering of 6,325,000 shares of common stock at a price of $12.35 per share to the public. The Company received approximately $73.3 million of net proceeds from the offering, after deducting $4.8 million for the underwriting discount and other stock issuance costs paid by the Company.

XML

EQUITY (Details) (USD $)	0 Months Ended	6 Months Ended
	Jun. 21, 2013	Jun. 30, 2013
EQUITY
Issuance of stock on underwritten public offering (in shares)	6,325,000
Price of common stock (in dollars per share)	$ 12.35
Net proceeds received from the offerings	$ 73,300,000	$ 73,302,000
Underwriting discount and other stock issuance costs	$ 4,800,000

XML

INCOME TAXES

6 Months Ended

Jun. 30, 2013

INCOME TAXES

INCOME TAXES

(9) INCOME TAXES

The Company is subject to taxation in the U.S. and various state jurisdictions. All of the Company’s tax years are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses.

Under financial accounting standards, deferred tax assets or liabilities are computed based on the differences between the financial statement and income tax bases of assets and liabilities using the enacted tax rates. Deferred income tax expense or benefit represents the change in the deferred tax assets or liabilities from period to period.

A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, management has determined that a full valuation allowance at June 30, 2013 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact the Company’s effective tax rate.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.  At June 30, 2013 the Company had no unrecognized tax benefits, nor are there any tax positions where it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the 12 months following June 30, 2013.

XML

FAIR VALUE MEASUREMENTS

6 Months Ended

Jun. 30, 2013

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

(5) FAIR VALUE MEASUREMENTS

The FASB has issued authoritative guidance which requires that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions.  Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy.  The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs.  Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.  Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.

The three levels of the fair value hierarchy established are as follows:

Level 1	Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3	Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.

Fixed-income securities and mutual funds are valued using a third party pricing agency. The valuation is based on observable inputs including pricing for similar assets and other observable market factors. There has been no material change from period to period.  The estimated fair value of our long-term debt based on a market approach was approximately $1.0 million as of June 30, 2013 and December 31, 2012 and represent Level 2 measurements.  When determining the estimated fair value of our long-term debt, we used market-based risk measurements, such as credit risk.

The following table presents the Company’s fair value measurements as of June 30, 2013 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Amounts in the table are in thousands.

			Fair Value Measurement at June 30, 2013 Using:
			Quoted Prices in Active		Significant Other		Significant Unobservable
	Fair Value at		Markets for Identical Assets		Observable Inputs		Inputs
Description	June 30, 2013		(Level 1)		(Level 2)		(Level 3)
Cash and cash equivalents
Cash and money market	$	12,567	$	12,567	$	—	$	—
Certificates of deposit	8,951		—		8,951		—
Available-for-Sale
Marketable securities
U.S. government agency securities	49,196		—		49,196		—
Corporate bonds	73,736		—		73,736		—
Certificates of deposit	8,284		—		8,284		—
Commercial paper	4,995		—		4,995		—
Total	$	157,729	$	12,567	$	145,162	$	—

The following table presents the Company’s fair value measurements as of December 31, 2012 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall.  Amounts in the table are in thousands.

			Fair Value Measurement at December 31, 2012 Using:
			Quoted Prices in Active		Significant Other		Significant Unobservable
	Fair Value at		Markets for Identical Assets		Observable Inputs		Inputs
Description	December 31, 2012		(Level 1)		(Level 2)		(Level 3)
Cash and cash equivalents
Cash and money market	$	13,095	$	13,095	$	—	$	—
Corporate bonds	250		—		250		—
Available-for-Sale
Marketable securities
U.S. government agency securities	44,308		—		44,308		—
Certificates of deposit	5,939		—		5,939		—
Corporate bonds	43,330		—		43,330		—
Commercial paper	1,199		—		1,199		—
Total	$	108,121	$	13,095	$	95,026	$	—

As of June 30, 2013 and December 31, 2012 there were available-for-sale securities in a continuous unrealized loss position for less than twelve months where the total unrealized losses were $58,184 and $4,800 respectively. At June 30, 2013 and December 31, 2012 there were no available-for-sale securities in a continuous loss position for greater than twelve months.

The following summarizes contractual underlying maturities of the Company’s available-for-sale investments in debt securities at June 30, 2013 (in thousands):

	Cost		Fair Value
Due in one year or less	$	71,915	$	71,940
Due after one year through two years	64,279		64,271
	$	136,194	$	136,211

XML

Condensed Statements of Cash Flows (Parenthetical)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Condensed Statements of Cash Flows
Issuance of shares of common stock to fund the Company's 401(k) matching contribution	30,534	32,872
Conversion of accrued expenses into shares of common stock	34,442	34,336

XML

INCOME TAXES (Details) (USD $)	Jun. 30, 2013
INCOME TAXES
Unrecognized tax benefits	$ 0

XML

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2013

STOCK-BASED COMPENSATION

Schedule of valuation assumptions

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Option Plan Shares
Risk-free interest rates	0.94%		0.82%		0.94% - 1.15%		0.82% - 0.84%
Expected term (in years)	6		6		6		6
Expected volatility	82.9%		87.1%		82.9% - 84.0%		87.1% - 91.6%
Dividend yield	0%		0%		0%		0%
Weighted average fair value per share of options granted during the period	$	6.55	$	7.38	$	7.66	$	6.86
ESPP Shares
Risk-free interest rates	0.11% - 0.20%		0.19% - 0.27%		0.11% - 0.20%		0.19% - 0.27%
Expected term (in years)	0.5-2		0.5 - 2		0.5-2		0.5 - 2
Expected volatility	39.1% - 45.6%		39.6% - 54.9%		39.1% - 45.6%		39.6% - 54.9%
Dividend yield	0%		0%		0%		0%
Weighted average fair value per share of stock purchase rights granted during the period	$	2.80	$	3.47	$	2.80	$	3.47

Summary of stock option activity under the Stock Plans

					Weighted
			Weighted		Average
			Average		Remaining	Aggregate
			Exercise		Contractual	Intrinsic
Options	Shares		Price		Term (Years)	Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 2013	6,181,996		$	2.62	6.6	$	49,439
Granted	240,570		$	10.72
Exercised	(98,869	)	$	4.99
Forfeited	(74,250	)	$	8.67
Outstanding, June 30, 2013	6,249,447		$	2.83	6.2	$	69,266
Exercisable, June 30, 2013	5,205,858		$	1.84	5.8	$	62,849
Vested and expected to vest June 30, 2013	6,220,586		$	2.84	6.2	$	69,089

(1)The aggregate intrinsic value of options outstanding, exercisable and vested and expected to vest is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s common stock for options that had exercise prices that were lower than the $13.91 market price of the Company’s common stock at June 30, 2013.  The total intrinsic value of options exercised during the six months ended June 30, 2013 was $0.5 million. The total intrinsic value of options exercised during the six months ended June 30, 2012 was $3.4 million.

Summary of restricted stock activity under the Stock Plans

			Weighted
	Restricted		Average Grant
	Shares		Date Fair Value
Outstanding, January 1, 2013	813,955		$	8.51
Granted	581,124		$	10.77
Released	(166,843	)	$	8.63
Forfeited	(352,836	)	$	9.45
Outstanding, June 30, 2013	875,400		$	9.61

XML

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2013

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

(8) RELATED PARTY TRANSACTIONS

During the three months ended September 30, 2012, the Company entered into a one year consulting agreement with a non-employee director under which the director provides advisory services in support of the Company’s commercialization activities. In accordance with the agreement, the Company granted a restricted stock award for 4,873 shares of common stock that vests over one year, and will make cash payments totaling $60,000 over the one year term of the agreement.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	6 Months Ended
	Jun. 30, 2013 item	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Restricted cash	$ 0	$ 0		$ 0
Number of objectives of the entity's investment strategy	2
Realized losses		0	0
Realized gains		2,760	2,528
Minimum contractual term of certain current investments which can be liquidated	1 year
Available-for-sale securities
Amortized Cost	136,194	136,194		94,698
Gains in Accumulated Other Comprehensive Income	52	52		78
Losses in Accumulated Other Comprehensive Income	(35)	(35)
Estimated Fair Value	136,211	136,211		94,776
U.S. government agency securities
Available-for-sale securities
Amortized Cost	49,156	49,156		44,270
Gains in Accumulated Other Comprehensive Income	40	40		38
Estimated Fair Value	49,196	49,196		44,308
Corporate bonds
Available-for-sale securities
Amortized Cost	73,771	73,771		43,303
Gains in Accumulated Other Comprehensive Income				27
Losses in Accumulated Other Comprehensive Income	(35)	(35)
Estimated Fair Value	73,736	73,736		43,330
Certificates of deposit
Available-for-sale securities
Amortized Cost	8,272	8,272		5,926
Gains in Accumulated Other Comprehensive Income	12	12		13
Estimated Fair Value	8,284	8,284		5,939
Commercial paper
Available-for-sale securities
Amortized Cost	4,995	4,995		1,199
Estimated Fair Value	$ 4,995	$ 4,995		$ 1,199

XML

FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jun. 30, 2013

FAIR VALUE MEASUREMENTS

Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall

The following table presents the Company’s fair value measurements as of June 30, 2013 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Amounts in the table are in thousands.

			Fair Value Measurement at June 30, 2013 Using:
			Quoted Prices in Active		Significant Other		Significant Unobservable
	Fair Value at		Markets for Identical Assets		Observable Inputs		Inputs
Description	June 30, 2013		(Level 1)		(Level 2)		(Level 3)
Cash and cash equivalents
Cash and money market	$	12,567	$	12,567	$	—	$	—
Certificates of deposit	8,951		—		8,951		—
Available-for-Sale
Marketable securities
U.S. government agency securities	49,196		—		49,196		—
Corporate bonds	73,736		—		73,736		—
Certificates of deposit	8,284		—		8,284		—
Commercial paper	4,995		—		4,995		—
Total	$	157,729	$	12,567	$	145,162	$	—

The following table presents the Company’s fair value measurements as of December 31, 2012 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall.  Amounts in the table are in thousands.

			Fair Value Measurement at December 31, 2012 Using:
			Quoted Prices in Active		Significant Other		Significant Unobservable
	Fair Value at		Markets for Identical Assets		Observable Inputs		Inputs
Description	December 31, 2012		(Level 1)		(Level 2)		(Level 3)
Cash and cash equivalents
Cash and money market	$	13,095	$	13,095	$	—	$	—
Corporate bonds	250		—		250		—
Available-for-Sale
Marketable securities
U.S. government agency securities	44,308		—		44,308		—
Certificates of deposit	5,939		—		5,939		—
Corporate bonds	43,330		—		43,330		—
Commercial paper	1,199		—		1,199		—
Total	$	108,121	$	13,095	$	95,026	$	—

Summary of contractual maturities available for the sale of investments in debt securities

The following summarizes contractual underlying maturities of the Company’s available-for-sale investments in debt securities at June 30, 2013 (in thousands):

	Cost		Fair Value
Due in one year or less	$	71,915	$	71,940
Due after one year through two years	64,279		64,271
	$	136,194	$	136,211

XML

Document and Entity Information	6 Months Ended
	Jun. 30, 2013	Jul. 31, 2013
Document and Entity Information
Entity Registrant Name	EXACT SCIENCES CORP
Entity Central Index Key	0001124140
Document Type	10-Q
Document Period End Date	Jun. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		70,698,697
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2

XML

OPERATING LEASE (Tables)

6 Months Ended

Jun. 30, 2013

OPERATING LEASE

Schedule of future minimum payments under the operating lease

Future minimum payments under the operating lease are as follows as of June 30, 2013. Amounts included in the table are in thousands.

Year Ending December 31,
2013	$	112
2014	676
2015	680
2016	684
2017	689
2018	578
Total lease obligations	$	3,419